WO2023012515A2 - Subcutaneous unit dosage forms - Google Patents

Subcutaneous unit dosage forms Download PDF

Info

Publication number
WO2023012515A2
WO2023012515A2 PCT/IB2022/000443 IB2022000443W WO2023012515A2 WO 2023012515 A2 WO2023012515 A2 WO 2023012515A2 IB 2022000443 W IB2022000443 W IB 2022000443W WO 2023012515 A2 WO2023012515 A2 WO 2023012515A2
Authority
WO
WIPO (PCT)
Prior art keywords
biologic
dose
unit dosage
efgartigimod
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2022/000443
Other languages
English (en)
French (fr)
Other versions
WO2023012515A3 (en
Inventor
Antoinetta Jacoba Maria VAN BRAGT
Peter Ulrichts
Erik HOFMAN
Peter Verheesen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ArgenX BVBA
Original Assignee
ArgenX BVBA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP22764840.9A priority Critical patent/EP4380618A2/en
Application filed by ArgenX BVBA filed Critical ArgenX BVBA
Priority to KR1020247006620A priority patent/KR20240040104A/ko
Priority to CN202280059734.XA priority patent/CN117897172A/zh
Priority to AU2022322077A priority patent/AU2022322077A1/en
Priority to IL310608A priority patent/IL310608A/en
Priority to CA3228105A priority patent/CA3228105A1/en
Priority to MX2024001631A priority patent/MX2024001631A/es
Priority to JP2024506201A priority patent/JP2024530152A/ja
Publication of WO2023012515A2 publication Critical patent/WO2023012515A2/en
Publication of WO2023012515A3 publication Critical patent/WO2023012515A3/en
Priority to US18/431,585 priority patent/US20240325528A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Definitions

  • IV administration is the primary method of administering many biologies.
  • IV administration due to the requirements for IV administration, there are issues with patient compliance.
  • SC administration of biologies is an alternative to IV administration.
  • SC administration of biologies has several advantages. For example, SC administration reduces the incidence of systemic reactions, lower risk of infections, does not require sometimes-difficult IV access, and is more convenient for patients.
  • unit dosage forms of a biologic that are determined based on a modeling approach, which matches a pharmacodynamic (PD) value of the SC dose with that of a known reference IV dose, while a pharmacokinetic (PK) value of the SC dose is less than that of the IV dose.
  • the unit dosage forms provided herein show comparable safety and efficacy as compared to a reference IV dose, and are therefore, non-inferior to the IV dose, providing patients with a more convenient alternative method of administration of a biologic.
  • the unit dosage forms disclosed herein comprise lower dosage amounts of a biologic, which could decrease adverse events in patients and could allow for subcutaneous administration as an alternative for biologies that are generally administered by IV infusion.
  • unit dosage forms for subcutaneous administration of a biologic wherein the biologic has an RDi V , which results in a PKi V and a PDiv in a subject upon intravenous administration; the unit dosage form comprises an RD SC of the biologic, which results in a PK SC and a PD SC in a subject upon subcutaneous administration; and the ratio PK sc /PKi V is less than 0.8 and the ratio PD sc /PDi V is from 0.9 to 1.1.
  • unit dosage forms for subcutaneous administration of a biologic wherein the biologic has an RDi V , which results in a PKj v and a BLi V in a subject upon intravenous administration, the unit dosage form comprises an RD SC of the biologic, which results in a PK SC and a BL SC in a subject upon subcutaneous administration; and the ratio PKsc/PKiv is less than about 0.8 and the ratio BL sc /BLi V is of about 0.9 to about 1.1.
  • unit dosage forms for subcutaneous administration of a biologic wherein the amount subcutaneous dose of the biologic in the unit dosage form was determined by a method comprising the steps of (a) administering a subcutaneous dose of the biologic to a subject, wherein the biologic has an RDi V , which results in a PKi V and a BLi V ; (b) determining the BL SC ; (c) determining the PK SC of the biologic; and (d) determining a subcutaneous dose that would result in a BL SC I BLi V -ratio of about 0.9 to about 1.1 and a PKsc/PKiv ratio less than about 0.8.
  • the BL SC and the BLi V are levels of total serum IgG in the subject.
  • the total serum IgG in the subject is analyzed using a bioanalytical method.
  • the bioanalytical method is ELISA or automated diagnostic analyzer (IVD).
  • the subject is a healthy volunteer or a non-human animal.
  • the PDi V and the PD SC values are the AUC. In an embodiment, the PK sc /PKi V ratio is less than 0.7. In an embodiment, the PK sc /PKi V ratio is less than 0.6. In an embodiment, the PK sc /PKi V ratio is about 0.8, about 0.7, about 0.6, or about 0.5. [0013] In an embodiment, the PDi V and the PD SC values are total serum IgG reduction.
  • the PD sc /PDi V ratio is from 0.9 to 1.1. In an embodiment, the PD sc /PDi V ratio is 0.9, 1.0, or 1.1.
  • the biologic is selected from the group consisting of antibodies, antibody fragments, anticoagulants, blood factors, bone morphogenetic proteins, enzymes, fusion proteins, growth factors, hormones, interferons, interleukins, and thrombolytics.
  • the biologic is an antibody, for example, an anti-FcRn antibody.
  • the antibody is rozanolixizumab (UCB7665), nipocalimab (M281), orilanolimab (ALXN1830/SYNT001), or batoclimab (IMVT- 1401/RVT1401/HBM9161).
  • the biologic comprises or consists of a variant Fc region, or FcRn binding fragment thereof, which binds to FcRn with a higher affinity at pH5.5 as compared to a corresponding wild-type Fc region.
  • the biologic antagonizes FcRn binding to an antibody Fc region.
  • the biologic is efgartigimod.
  • the RDi V is from 10 mg/kg to 25 mg/kg and the RD SC is from about 1000 mg to about 2000 mg. In an embodiment, the RDi V is 10 mg/kg and the RD SC is about 1000 mg. In an embodiment, the RDi V is 25 mg/kg and the RD SC is about 2000 mg.
  • the unit dosage form further comprises a hyaluronidase enzyme.
  • the hyaluronidase enzyme comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 5-96.
  • the hyaluronidase enzyme is rHuPH20.
  • the unit dosage form is co-administered with a hyaluronidase enzyme.
  • the hyaluronidase enzyme is rHuPH20.
  • the amount of hyaluronidase enzyme is from about 1000 U/ml to about 3000 U/ml. In an embodiment, the amount of hyaluronidase enzyme is about 1000 U/mL, about 1500 U/mL, about 2000 U/mL, about 2500 U/mL, or about 3000 U/mL. In an embodiment, the amount of hyaluronidase enzyme is 2000 U/mL.
  • the unit dosage form is for use in treatment of an autoimmune disease.
  • the autoimmune disease is selected from the group consisting of allogenic islet graft rejection, alopecia areata, ankylosing spondylitis, antiphospholipid syndrome, autoimmune Addison’s disease, Alzheimer’s disease, antineutrophil cytoplasmic autoantibodies (ANCA), autoimmune diseases of the adrenal gland, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune myocarditis, autoimmune neutropenia, autoimmune oophoritis and orchitis, immune thrombocytopenia (ITP or idiopathic thrombocytopenic purpura or idiopathic thrombocytopenia purpura or immune mediated thrombocytopenia), autoimmune urticaria, Behcet’s disease, bullous pemphigoid (BP), cardiomyopathy, Castleman’s syndrome, celiac spruce-dermatitis, chronic fatigue immune
  • Also provided herein is method of determining a therapeutically effective dose of a biologic for subcutaneous administration comprising: (a) administering a subcutaneous dose of the biologic to a subject, wherein the biologic has an RDi V , which results in a PKiv and a BLi V ; (b) determining the BL SC of the biologic; (c) determining the PK SC of the biologic; and (d) determining a subcutaneous dose that would result in a BL SC I BLi V ratio of about 0.9 to about 1.1 and a PK sc /PKi V ratio less than about 0.8, thereby determining a therapeutically effective dose of the biologic for subcutaneous administration.
  • the subject is a healthy volunteer or a non-human animal.
  • the ratio PK sc /PKi V is less than 0.7. In an embodiment, the ratio PKsc/PKiv is less than 0.6. In an embodiment, the PKi V and the PK SC values are the AUC.
  • biologic is selected from the group consisting of antibodies, antibody fragments, anticoagulants, blood factors, bone morphogenetic proteins, enzymes, fusion proteins, growth factors, hormones, interferons, interleukins, and thrombolytics.
  • the BL SC and the BLi V are levels of total serum IgG in the subject.
  • the total serum IgG in the subject is analyzed using a bioanalytical method.
  • the bioanalytical method is ELISA or automated diagnostic analyzer (IVD).
  • the biologic is an antibody.
  • the antibody is an anti-FcRn antibody.
  • the anti-FcRn antibody is rozanolixizumab (UCB7665), nipocalimab (M281), orilanolimab (ALXN1830/SYNT001), or batoclimab (IMVT-1401 /RVT1401/HBM9161).
  • the biologic comprises or consists of a variant Fc region, or FcRn binding fragment thereof, which binds to FcRn with a higher affinity at pH5.5 as compared to a corresponding wild-type Fc region.
  • the biologic antagonizes FcRn binding to an antibody Fc region.
  • the biologic is efgartigimod.
  • the RDi V is 10 mg/kg. In an embodiment, wherein the RDi V is 25 mg/kg.
  • the therapeutically effective amount of the biologic is coadministered with a hyaluronidase enzyme.
  • the therapeutically effective amount of the biologic is administered before or after a hyaluronidase enzyme.
  • the hyaluronidase enzyme comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 5-96.
  • the hyaluronidase enzyme is rHuPH20.
  • the amount of hyaluronidase enzyme is from 1000 U/ml to 3000 U/ml, preferably 2000 U/mL.
  • Fc region or FcRn binding fragment thereof, wherein the Fc domains of the Fc region comprise the amino acids Y, T, E, K, F, and Y at EU Kabat positions 252, 254, 256, 433, 434, and 436 respectively, for use in treating myasthenia gravis in a human patient.
  • the instant disclosure provides a variant Fc region, or FcRn binding fragment thereof, wherein the Fc domains of the Fc region comprise the amino acids Y, T, E, K, F, and Y at EU Kabat positions 252, 254, 256, 433, 434, and 436 respectively, for use in treating myasthenia gravis in a human patient, wherein: the variant Fc region, or FcRn binding fragment thereof, is administered subcutaneously at a weekly dose of between 950 and 1050 mg, independent of the weight of the patient, and a total serum IgG reduction in the patient of at least 60% compared to baseline IgG level is obtained.
  • the weekly dose is about 950 mg, about 975 mg, about 1000 mg, about 1025 mg, or about 1050 mg. In an embodiment, the weekly dose is about 1000 mg.
  • a variant Fc region, or FcRn binding fragment thereof wherein the Fc domains of the Fc region comprise the amino acids Y, T, E, K, F, and Y at EU Kabat positions 252, 254, 256, 433, 434, and 436 respectively, for use in treating pemphigus vulgaris in a human patient.
  • the instant disclosure provides a variant Fc region, or FcRn binding fragment thereof, wherein the Fc domains of the Fc region comprise the amino acids Y, T, E, K, F, and Y at EU Kabat positions 252, 254, 256, 433, 434, and 436 respectively, for use in treating pemphigus vulgaris in a human patient, wherein: the variant Fc region, or FcRn binding fragment thereof, is administered subcutaneously at a weekly dose of between 1950 and 2050 mg, independent of the weight of the patient, and a total serum IgG reduction in the patient of at least 60% compared to baseline IgG level is obtained.
  • the weekly dose is about 1950 mg, about 1975 mg, about 2000 mg, about 2025 mg, or about 2050 mg. In an embodiment, the weekly dose is about 2000 mg.
  • the treatment comprises at least 2 weekly doses. In an embodiment, the treatment comprises at least 3 weekly doses. In an embodiment, the treatment comprises at least 4 weekly doses. In an embodiment, the treatment comprises at least 5 weekly doses. In an embodiment, the treatment comprises at least 6 weekly doses. In an embodiment, the treatment comprises at least 7 weekly doses. In an embodiment, the treatment comprises at least 8 weekly doses. In an embodiment, the treatment comprises at more than 8 weekly doses.
  • the variant Fc region, or FcRn binding fragment thereof is administered with a hyaluronidase enzyme.
  • the hyaluronidase enzyme comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 5-96.
  • the hyaluronidase enzyme is rHuPH20.
  • a total serum IgG reduction in the patient of about 60% compared to baseline IgG level is obtained. In an embodiment, a total serum IgG reduction in the patient of about 65%, about 70%, about 75%, or about 80% compared to baseline IgG level is obtained.
  • the percentage of total serum IgG reduction in the patient is achieved within 1 month from the first dose. In an embodiment, the percentage of total serum IgG reduction in the patient is achieved within 2 weeks, 3 weeks, 4 weeks, 5 weeks, or 6 weeks from the first dose. In an embodiment, the percentage of total serum IgG reduction in the patient is achieved within 31, 30, 29, 28, 27, 26, or 25 days from the first dose.
  • the maximum percentage of total serum IgG reduction in the patient is achieved within 1 month from the first dose. In an embodiment, the maximum percentage of total serum IgG reduction in the patient is achieved within 2 weeks, 3 weeks, 4 weeks, 5 weeks, or 6 weeks from the first dose. In an embodiment, the maximum percentage of total serum IgG reduction in the patient is achieved within 31, 30, 29, 28, 27, 26, or 25 days from the first dose.
  • the total serum IgG level in the patient is reduced to 2000 to 4000 pg/mL. In an embodiment, the total serum IgG level in the patient is reduced to 2000 to
  • the total serum IgG level in the patient is reduced to 3000 to
  • the total serum IgG level in the patient is reduced to 2500 to
  • the total serum IgG level in the patient is reduced to 2750 to
  • the total serum IgG in the patient is analyzed using a bioanalytical method. In an embodiment, the total serum IgG in the patient is analyzed using ELISA or automated diagnostic analyzer (IVD).
  • IVD automated diagnostic analyzer
  • At least one of the IgG subtypes is reduced.
  • IgGl is reduced.
  • IgG2 is reduced.
  • IgG3 is reduced.
  • IgG4 is reduced.
  • the variant Fc region is efgartigimod.
  • Figures 1A-1B are graphs showing serum efgartigimod levels in patients from historical data following IV and SC administration of efgartigimod with or without rHuPH20 ( Figure 1A) and following SC co-administration of efgartigimod with rHuPH20 ( Figure IB).
  • Figures 2A-C are graphs showing total IgG reduction following single SC doses of 750 mg ( Figure 2A), 1250 mg (Figure 2B), and 1750 mg ( Figure 2C), coadministered with rHuPH20, compared to historical data following an SC dose of 10 mg/kg, without rHuPH20, and an IV dose of 10 mg/kg, without rHuPH20.
  • Figure 3 is a graph showing visual predictive checks of efgartigimod concentration in the study described in Example 1. Grey dots are observed data; blue solid line is observed median; red dashed lines are 10 th and 90 th percentiles of observations; grey area is 80% prediction interval.
  • Figure 4 is a graph showing a visual predictive check of efgartigimod concentration on log-scale in a previous study. Grey dots are observed data; blue solid line is observed median; red dashed lines are 10 th and 90 th percentiles of observations; grey area is 80% prediction interval.
  • Figure 5 is a graph showing a comparison of 10 mg/kg SC of efgartigimod without rHuPH20 (blue lines) and with rHuPH20 (red lines).
  • Blue dots are observations from healthy volunteers receiving 10 mg/kg SC efgartigimod without rHuPH20; red dots are observations from healthy volunteers receiving 10 mg/kg SC efgartigimod in combination with rHuPH20; blue lines are population predictions of efgartigimod concentration without rHuPH20; red lines are population predictions of efgartigimod concentration with rHuPH20.
  • Figure 6 is a graph showing visual predictive checks of total IgG concentrations in the study described in Example 1 , obtained with the PK/PD model in which the parameters were optimized using data from previous studies. Grey dots are observed data; blue solid line is observed median; red dashed lines are 10 th and 90 th percentiles of observations; grey area is 80% prediction interval.
  • Figure 7 is a graph showing visual predictive checks of total IgG reduction in the study described in Example 1, obtained with the PK/PD model in which the parameters were optimized on data from previous studies. Grey dots are observed data; blue solid line is observed median; red dashed lines are 10 th and 90 th percentiles of observations; grey area is 80% prediction interval.
  • Figure 8 is a graph showing visual predictive checks of total IgG concentrations in the study described in Example 1 , obtained with the PK/PD model accounting for the effect compartment. Grey dots are observed data; blue solid line is observed median; red dashed lines are 10 th and 90 th percentiles of observations; grey area is 80% prediction interval.
  • Figure 9 is a graph showing visual predictive checks of total IgG reduction in the study described in Example 1, obtained with the PK/PD model accounting for the effect compartment. Grey dots are observed data; blue solid line is observed median; red dashed lines are 10 th and 90 th percentiles of observations; grey area is 80% prediction interval.
  • Figure 10 is a graph showing visual predictive checks of total IgG concentrations in historical data, obtained with the PK/PD model accounting for the effect compartment. Grey dots are observed data; blue solid line is observed median; red dashed lines are 10 th and 90 th percentiles of observations; grey area is 80% prediction interval.
  • Figure 11 is a graph showing visual predictive checks of total IgG reduction in historical data, obtained with the PK/PD model accounting for the effect compartment. Grey dots are observed data; blue solid line is observed median; red dashed lines are 10 th and 90 th percentiles of observations; grey area is 80% prediction interval.
  • Figure 12 is a graph showing the area under the effect curve (AUEC) between day 22 and 29 determined from the total IgG reduction simulations.
  • the solid and dashed horizontal lines are the median and 90% CI of AUEC between day 22 and 29 obtained with the 10 mg/kg IV QW dose of efgartigimod.
  • the points and bars are the median and 90% CI of AUEC between day 22 and 29 obtained with the SC QW doses of efgartigimod.
  • Figure 13 is a graph showing the simulated maximum total IgG reduction between day 22 and 29.
  • the solid and dashed horizontal lines are the median and 90% CI of maximum total IgG reduction obtained with the 10 mg/kg IV QW dose of efgartigimod.
  • the points and bars are the median and 90% CI of total IgG reduction obtained with the SC QW doses of efgartigimod.
  • Figure 14 is a graph showing the simulated maximum total IgG at day 29.
  • the solid and dashed horizontal lines are the median and 90% CI of maximum total IgG reduction obtained with the 10 mg/kg IV weekly dose of efgartigimod.
  • the points and bars are the median and 90% CI of total IgG reduction obtained with the SC weekly doses of efgartigimod.
  • Figure 15 is a graph showing the percentage of simulated AUEC22-29 (obtained with different efgartigimod PH20 SC weekly doses ranging between 750 mg and 1750 mg (with 25 mg increments)) greater than the median AUEC22-29 obtained with 10 mg/kg IV of efgartigimod weekly.
  • Figure 16 is a graph showing the percentage of simulated maximum total IgG reduction (IgGt supp) between day 22 and day 29 (obtained with different efgartigimod PH20 SC weekly doses ranging between 750 mg and 1750 mg (with 25 mg increments)) less than the median of the maximum total IgG reduction between day 22 and day 29 obtained with 10 mg/kg IV of efgartigimod weekly.
  • Vertical dashed line 975 mg
  • Horizontal dashed line percentage obtained with 975 mg efgartigimod PH20 SC weekly.
  • Figure 17 is a graph showing the percentage of simulated total IgG reduction (IgGt supp) on day 29 (trough) (obtained with different efgartigimod PH20 SC weekly doses ranging between 750 mg and 1750 mg (with 25 mg increments)) less than the median of total IgG reduction on day 29 obtained with 10 mg/kg IV of efgartigimod weekly.
  • Figure 18 is a graph showing simulated AUEC in different time intervals obtained with 1000 mg efgartigimod PH20 SC weekly and 10 mg/kg efgartigimod IV weekly. Points and bars: median and 5th and 95th percentiles of AUEC.
  • Figure 19 is a graph showing simulated maximum total IgG reduction in different time intervals obtained with 1000 mg efgartigimod PH20 SC weekly and 10 mg/kg efgartigimod IV weekly. Points and bars: median and 5th and 95th percentiles of maximum total IgG reduction.
  • Figure 20 is a graph showing simulated total IgG reduction, before doses on days 8, 15, 22, and 29, obtained with 1000 mg efgartigimod PH20 SC weekly and 10 mg/kg efgartigimod IV weekly. Points and bars: median and 5th and 95th percentiles of total IgG reduction.
  • Figure 21 is a graph showing simulated profiles of total IgG reduction after 1000 mg efgartigimod PH20 SC QW and 10 mg/kg IV of efgartigimod QW. Solid lines and areas: median, 5th and 95th percentiles of total IgG reduction; vertical dashed lines: day 22 and day 29.
  • Figure 22 is a schematic of the clinical trial protocol for subcutaneous dosing of efgartigimod co-formulated with rHuPH20.
  • Figure 23 is a graph showing mean (SE) of total IgG levels (pg/mL) over time during and after 4 weekly administrations of 1000 mg efgartigimod-PH20 SC or 10 mg/kg efgartigimod IV.
  • Figure 24 is a graph showing mean (SE) percent change from baseline in total IgG over time during and after 4 weekly administrations of 1000 mg efgartigimod- PH20 SC or 10 mg/kg efgartigimod IV.
  • Figure 25 is a graph showing mean difference and 95% 2- sided confidence intervals for the difference in change from baseline in total IgG between 4 weekly administrations of 1000 mg efgartigimod-PH20 SC and 10 mg/kg efgartigimod IV.
  • Figure 26 is a graph showing mean (SD) efgartigimod serum concentrationtime profiles after the fourth weekly administration of 1000 mg efgartigimod-PH20 SC or 10 mg/kg efgartigimod IV (day 22).
  • the instant disclosure provides unit dosage forms of a biologic that are determined based on a modeling approach, which matches a pharmacodynamic (PD) value of the SC dose with that of a known reference IV dose, while a pharmacokinetic (PK) value of the SC dose is less than that of the IV dose.
  • the unit dosage forms provided herein show comparable safety and efficacy as compared to a reference IV dose, and are therefore, noninferior to the IV dose, providing patients with a more convenient alternative method of administration of a biologic.
  • unit dosage forms for subcutaneous administration of a biologic wherein the biologic has an RDi V , which results in a PKi V and a PDiv in a subject upon intravenous administration; the unit dosage form comprises an RD SC of the biologic, which results in a PK SC and a PD SC in a subject upon subcutaneous administration; and the ratio PK sc /PKi V is less than 0.8 and the ratio PD sc /PDi V is from 0.9 to 1.1.
  • unit dosage form is a pharmaceutical drug product in the form in which it is marketed for use, with a specific mixture of active ingredients and inactive components (excipients), and apportioned into a particular dose.
  • Unit dosage forms provided herein can refer to physically discrete units suitable as unitary dosages for human and/or animal subjects, each unit containing a predetermined quantity of active material (e.g., about 500 mg to about 2500 mg of efgartigimod or about 500 mg to about 2500 mg of efgartigimod and about 1000 U/ml to about 3000 U/ml rHuPH20) calculated to produce the desired therapeutic effect in association with the required pharmaceutical diluent, carrier, or vehicle.
  • active material e.g., about 500 mg to about 2500 mg of efgartigimod or about 500 mg to about 2500 mg of efgartigimod and about 1000 U/ml to about 3000 U/ml rHuPH20
  • Non-limiting examples of suitable unit dosage forms are vials, tablets, capsules, troches, suppositories, powder packets, wafers, cachets, ampules, pre-filled syringes, segregated multiples of any of the foregoing, and other forms as herein described or generally known in the art.
  • the term “biologic” refers to a product that is produced from living organisms or contain components of living organisms, for example antibodies or antibody fragments or recombinant proteins.
  • the biologic is efgartigimod.
  • the term “reference dose” refers to an arbitrary intravenous dose of the biologic of which the PK and/or PD (PKi V and PDi V ) are used as reference values.
  • the reference dose may be an approved drug dose, a specific determined drug dose, or an optimal drug dose as determined during clinical trial(s).
  • the reference dose of the biologic can be the approved dose by a regulatory authority (such as the Food and Drug Administration (FDA) in US or European Medicines Agency (EMA) in Europa) for administration to a patient.
  • FDA Food and Drug Administration
  • EMA European Medicines Agency
  • RDi V refers to a dose of a biologic for intravenous administration to a patient, generally in one single administration.
  • RD SC refers to a dose of a biologic for subcutaneous administration to a patient, generally in one single administration.
  • PKi V refers to an experimentally determined pharmacokinetic value for an intravenously administered drug. This value is used to describe the absorption, distribution, metabolism, and excretion of the drug in the (human) body.
  • PK SC refers to a pharmacokinetic value for a subcutaneously administered drug. This value is used to describe the absorption, distribution, metabolism, and excretion of the drug in the (human) body.
  • a PK SC can be determined based on pharmacokinetic modeling (predictive modeling methods).
  • a PK SC can be determined experimentally or empirically (e.g., based on experience).
  • PDi V refers to an experimentally determined pharmacodynamic value of an intravenously administered drug. In an embodiment, this value is used to describe the biochemical, physiologic, and molecular effects (clinical effects) of the drug on the (human) body and involves receptor binding (including receptor sensitivity), post receptor effects, and chemical interactions.
  • PD SC refers to a pharmacodynamic value of a subcutaneously administered drug. In an embodiment, this value is used to describe the biochemical, physiologic, and molecular effects (clinical effects) of the drug on the (human) body and involves receptor binding (including receptor sensitivity), post receptor effects, and chemical interactions.
  • a PD SC can be determined based on pharmacodynamic modeling (predictive modeling methods).
  • PD SC can be determined experimentally or empirically (e.g., based on experience).
  • BLi V refers to the level of a biomarker (e.g., IgG) following intravenous administration of a biologic to a subject, compared to a baseline level of the biomarker in the subject.
  • a biomarker e.g., IgG
  • BL SC refers to the level of a biomarker (e.g., IgG) following subcutaneous administration of a biologic to a subject, compared to a baseline level of the biomarker in the subject.
  • a biomarker e.g., IgG
  • Cmax refers to the maximum serum concentration of a biologic.
  • AUC refers to the area under the serum concentration versus time curve. The AUC is based on the rate and extent of elimination of a biologic following administration.
  • Fc domain refers to the portion of a single immunoglobulin heavy chain beginning in the hinge region and ending at the C-terminus of the antibody. Accordingly, a complete Fc domain comprises at least a portion of a hinge (e.g., upper, middle, and/or lower hinge region) domain, a CH2 domain, and a CH3 domain.
  • a hinge e.g., upper, middle, and/or lower hinge region
  • Fc region refers to the portion of a native immunoglobulin formed by the Fc domains of its two heavy chains.
  • a native Fc region is homodimeric.
  • variable Fc region refers to an Fc region with one or more alteration(s) relative to a native Fc region. Alteration can include amino acid substitutions, additions and/or deletions, linkage of additional moieties, and/or alteration the native glycans.
  • the term encompasses heterodimeric Fc regions where each of the constituent Fc domains is different. The term also encompasses single chain Fc regions where the constituent Fc domains are linked together by a linker moiety.
  • FcRn binding fragment refers to a portion of an Fc region that is sufficient to confer FcRn binding.
  • hyaluronidase enzyme refers to an enzyme that catalyzes the breakdown of hyaluronic acid in the body, which may increase the permeability of tissue to fluids or drugs (e.g., a subcutaneously administered biologic).
  • the hyaluronidase enzyme is a recombinant human hyaluronidase PH20 enzyme (rHuPH20) which degrades hyaluronan (HA).
  • IgG reduction refers to a decline of (disease-causing) immunoglobulin G (IgG) antibodies, e.g., in a patient’s blood serum.
  • baseline IgG level refers to the IgG level in a patient, e.g., in a patient’s blood, prior to the first administration (e.g., intravenous, or subcutaneous administration) of a biologic.
  • bioanalytical method refers to a bioanalytical assay that is used for the quantification of molecules (e.g., proteins, antibodies such as IgGs, and therapeutic agents) in support of pharmacokinetic evaluations, for example, to measure the total IgG in a serum sample.
  • the bioanalytical method is an ELISA.
  • the bioanalytical method is an automated diagnostic analyzer (IVD).
  • the instant disclosure provides unit dosage forms of a biologic for subcutaneous administration to a subject.
  • These unit dosage forms comprise an effective amount of a biologic, wherein the effective amount is determined based on a modeling approach, which matches a pharmacodynamic (PD) value of the SC dose with that of a known reference IV dose, while a pharmacokinetic (PK) value of the SC dose is less than that of the IV dose.
  • PD pharmacodynamic
  • PK pharmacokinetic
  • the unit dosage forms disclosed herein comprise lower dosage amounts of a biologic, which could decrease adverse events in patients and could allow for subcutaneous administration as an alternative for biologies that are generally administered by IV infusion.
  • unit dosage forms for subcutaneous administration of a biologic wherein the biologic has an RDi V , which results in a PKi V and a PDiv in a subject upon intravenous administration; the unit dosage form comprises an RD SC of the biologic, which results in a PK SC and a PD SC in a subject upon subcutaneous administration; and the ratio PK sc /PKi V is less than 0.8 and the ratio PD sc /PDi V is from 0.9 to 1.1.
  • unit dosage forms for subcutaneous administration of a biologic wherein the biologic has an RDi V , which results in a PKi V and a BLi V in a subject upon intravenous administration, the unit dosage form comprises an RD SC of the biologic, which results in a PK SC and a BL SC in a subject upon subcutaneous administration; and the ratio PKsc/PKiv is less than about 0.8 and the ratio BL sc /BLi V is of about 0.9 to about 1.1.
  • unit dosage forms for subcutaneous administration of a biologic wherein the amount subcutaneous dose of the biologic in the unit dosage form was determined by a method comprising the steps of (a) administering a subcutaneous dose of the biologic to a subject, wherein the biologic has an RDi V , which results in a PKi V and a BLi V ; (b) determining the BL SC ; (c) determining the PK SC of the biologic; and (d) determining a subcutaneous dose that would result in a BL SC I BLi V ratio of about 0.9 to about 1.1 and a PKsc/PKiv ratio less than about 0.8.
  • Also provided herein is method of determining a therapeutically effective dose of a biologic for subcutaneous administration comprising: (a) administering a subcutaneous dose of the biologic to a subject, wherein the biologic has an RDi V , which results in a PKiv and a BLi V ; (b) determining the BL SC of the biologic; (c) determining the PK SC of the biologic; and (d) determining a subcutaneous dose that would result in a BL SC I BLi V ratio of about 0.9 to about 1.1 and a PK sc /PKi V ratio less than about 0.8, thereby determining a therapeutically effective dose of the biologic for subcutaneous administration.
  • the subject is a healthy volunteer or a non-human animal.
  • the ratio PK sc /PKi V is less than 0.7. In an embodiment, the ratio PKsc/PKiv is less than 0.6. In an embodiment, the PKi V and the PK SC values are the AUC. [00109] In an embodiment, the BL SC and the BLi V are levels of total serum IgG the subject. In an embodiment, the total serum IgG in the subject is analyzed using a bioanalytical method. In an embodiment, the bioanalytical method is ELISA or automated diagnostic analyzer (IVD).
  • the biologic is an antibody molecule.
  • the antibody molecule binds FcRn.
  • the antibody molecule comprises an Fc domain engineered for optimized binding to FcRn.
  • the antibody molecule blocks FcRn.
  • the biologic is a variant Fc region, or FcRn binding fragment thereof.
  • the biologic is efgartigimod.
  • the biologic is selected from the group consisting of antibodies, antibody fragments, anticoagulants, blood factors, bone morphogenetic proteins, enzymes, fusion proteins, growth factors, hormones, interferons, interleukins, and thrombolytics.
  • the PK sc /PKi V ratio is less than 0.7. In an embodiment, the PKsc/PKiv ratio is less than 0.6. In an embodiment, the PK sc /PKi V ratio is about 0.8, about 0.7, about 0.6, about 0.5, about 0.47, or about 0.4. In an embodiment, the PK sc /PKi V ratio is about 0.8. In an embodiment, the PK sc /PKi V ratio is about 0.7. In an embodiment, the PK sc /PKi V ratio is about 0.6. In an embodiment, the PK sc /PKi V ratio is about 0.5. In an embodiment, the PKsc/PKiv ratio is about 0.4.
  • the PD sc /PDi V ratio is from 0.9 to 1.1. In an embodiment, the PDsc/PDiv ratio is 0.9, 1.0, or 1.1. In an embodiment, the PD sc /PDi V ratio is about 0.9, about 0.91, about 0.92, about 0.93, about 0.94, about 0.95, about 0.96, about 0.97, about 0.98, or about 0.99. In an embodiment, the PD sc /PDi V ratio is about 1.0, about 1.01, about 1.02, about 1.03, about 1.04, about 1.05, about 1.06, about 1.07, about 1.08, or about 1.09. In an embodiment, the PD sc /PDi V ratio is about 1.1, about 1.11, about 1.12, about 1.13, about 1.14, about 1.15, about 1.16, about 1.17, about 1.18, or about 1.19.
  • the BL S c/BLi V ratio is from 0.9 to 1.1. In an embodiment, the BLsc/BLiv ratio is 0.9, 1.0, or 1.1. In an embodiment, the BL S c/BLi V ratio is about 0.9, about 0.91, about 0.92, about 0.93, about 0.94, about 0.95, about 0.96, about 0.97, about 0.98, or about 0.99. In an embodiment, the BL S c/BLi V ratio is about 1.0, about 1.01, about 1.02, about 1.03, about 1.04, about 1.05, about 1.06, about 1.07, about 1.08, or about 1.09. In an embodiment, the BL S c/BLi V ratio is about 1.1, about 1.11, about 1.12, about 1.13, about 1.14, about 1.15, about 1.16, about 1.17, about 1.18, or about 1.19.
  • the PK sc /PKi V ratio is less than 0.8 and the PD sc /PDi V ratio is about 0.9. In an embodiment, the PK sc /PKi V ratio is less than 0.7 and the PD sc /PDi V ratio is about 0.9. In an embodiment, the PK sc /PKi V ratio is less than 0.6 and the PD sc /PDi V ratio is about 0.9. In an embodiment, the PK sc /PKi V ratio is about 0.7 and the PD sc /PDi V ratio is about 0.9.
  • the PK sc /PKi V ratio is about 0.6 and the PD sc /PDi V ratio is about 0.9. In an embodiment, the PK sc /PKi V ratio is about 0.5 and the PD sc /PDi V ratio is about 0.9. In an embodiment, the PK sc /PKi V ratio is about 0.4 and the PD sc /PDi V ratio is about 0.9.
  • the PK sc /PKi V ratio is less than 0.8 and the PD sc /PDi V ratio is about 1.0. In an embodiment, the PK sc /PKi V ratio is less than 0.7 and the PD sc /PDi V ratio is about 1.0. In an embodiment, the PK sc /PKi V ratio is less than 0.6 and the PD sc /PDi V ratio is about 1.0. In an embodiment, the PK sc /PKi V ratio is about 0.7 and the PD sc /PDi V ratio is about 1.0.
  • the PK sc /PKi V ratio is about 0.6 and the PD sc /PDi V ratio is about 1.0. In an embodiment, the PK sc /PKi V ratio is about 0.5 and the PD sc /PDi V ratio is about 1.0. In an embodiment, the PK sc /PKi V ratio is about 0.4 and the PD sc /PDi V ratio is about 1.0.
  • the PK sc /PKi V ratio is less than 0.8 and the PD sc /PDi V ratio is about 1.1. In an embodiment, the PK sc /PKi V ratio is less than 0.7 and the PD sc /PDi V ratio is about 1.1. In an embodiment, the PK sc /PKi V ratio is less than 0.6 and the PD sc /PDi V ratio is about 1.1. In an embodiment, the PK sc /PKi V ratio is about 0.7 and the PD sc /PDi V ratio is about 1.1.
  • the PK sc /PKi V ratio is about 0.6 and the PD sc /PDi V ratio is about 1.1. In an embodiment, the PK sc /PKi V ratio is about 0.5 and the PD sc /PDi V ratio is about 1.1. In an embodiment, the PK sc /PKi V ratio is about 0.4 and the PD sc /PDi V ratio is about 1.1.
  • the PK sc /PKi V ratio is less than 0.8 and the PD sc /PDi V ratio is about 0.9, about 0.91, about 0.92, about 0.93, about 0.94, about 0.95, about 0.96, about 0.97, about 0.98, or about 0.99.
  • the PK sc /PKi V ratio is less than 0.8 and the PDsc/PDiv ratio is about 1.0, about 1.01, about 1.02, about 1.03, about 1.04, about 1.05, about 1.06, about 1.07, about 1.08, or about 1.09.
  • the PK sc /PKi V ratio is less than 0.8 and the PD sc /PDi V ratio is about 1.1, about 1.11, about 1.12, about 1.13, about 1.14, about 1.15, about 1.16, about 1.17, about 1.18, or about 1.19.
  • the PK sc /PKi V ratio is less than 0.7 and the PD sc /PDi V ratio is about 0.9, about 0.91, about 0.92, about 0.93, about 0.94, about 0.95, about 0.96, about 0.97, about 0.98, or about 0.99.
  • the PK sc /PKi V ratio is less than 0.7 and the PDsc/PDiv ratio is about 1.0, about 1.01, about 1.02, about 1.03, about 1.04, about 1.05, about 1.06, about 1.07, about 1.08, or about 1.09.
  • the PK sc /PKi V ratio is less than 0.7 and the PD sc /PDi V ratio is about 1.1, about 1.11, about 1.12, about 1.13, about 1.14, about 1.15, about 1.16, about 1.17, about 1.18, or about 1.19. [00121] In an embodiment, the PK sc /PKi V ratio is less than 0.6 and the PD sc /PDi V ratio is about 0.9, about 0.91, about 0.92, about 0.93, about 0.94, about 0.95, about 0.96, about 0.97, about 0.98, or about 0.99.
  • the PK sc /PKi V ratio is less than 0.6 and the PDsc/PDiv ratio is about 1.0, about 1.01, about 1.02, about 1.03, about 1.04, about 1.05, about 1.06, about 1.07, about 1.08, or about 1.09.
  • the PK sc /PKi V ratio is less than 0.6 and the PD sc /PDi V ratio is about 1.1, about 1.11, about 1.12, about 1.13, about 1.14, about 1.15, about 1.16, about 1.17, about 1.18, or about 1.19.
  • the RDi V is from 10 mg/kg to 25 mg/kg and the RD SC is from about 1000 mg to about 2000 mg. In an embodiment, the RDi V is 10 mg/kg and the RD SC is about 1000 mg. In an embodiment, the RDi V is 25 mg/kg and the RD SC is about 2000 mg. In an embodiment, the RDi V is 10 mg/kg and the RD SC is about 2000 mg. In an embodiment, the RDiv is 25 mg/kg and the RD SC is about 1000 mg. In an embodiment, the RDi V is about 10 mg/kg to about 15 mg/kg and the RD SC is about 1000 mg to about 1500 mg. In an embodiment, the RDiv is 20 mg/kg to about 25 mg/kg and the RD SC is about 1500 mg to about 2000 mg.
  • the PKj v and the PK SC values are the AUC. In an embodiment, the PDi V and the PD SC values are the total serum IgG reduction in the subject.
  • the unit dosage form further comprises a hyaluronidase enzyme.
  • the hyaluronidase enzyme is rHuPH20.
  • the unit dosage form is co-administered with a hyaluronidase enzyme.
  • the hyaluronidase enzyme is rHuPH20.
  • the amount of hyaluronidase enzyme is from about 1000 U/ml to about 3000 U/ml. In an embodiment, the amount of hyaluronidase enzyme is about 1000 U/mL, about 1500 U/mL, about 2000 U/mL, about 2500 U/mL, or about 3000 U/mL. In an embodiment, the amount of hyaluronidase enzyme is 2000 U/mL.
  • the unit dosage form comprises from about 1000 U/ml to about 3000 U/ml of rHuPH20. In an embodiment, the unit dosage form comprises about 1000 U/mL, about 1500 U/mL, about 2000 U/mL, about 2500 U/mL, or about 3000 U/mL of rHuPH20. In an embodiment, the unit dosage form comprises 1000 U/mL of rHuPH20. In an embodiment, the unit dosage form comprises 1500 U/mL of rHuPH20. In an embodiment, the unit dosage form comprises 2000 U/mL of rHuPH20. In an embodiment, the unit dosage form comprises 2500 U/mL of rHuPH20. In an embodiment, the unit dosage form comprises 3000 U/mL of rHuPH20.
  • the biologic is an antibody molecule.
  • the antibody molecule comprises an Fc domain engineered for optimized binding to FcRn.
  • the antibody molecule blocks FcRn.
  • the biologic is efgartigimod.
  • the unit dosage form comprises about 500 mg to about 2500 mg of efgartigimod. In an embodiment, the unit dosage form comprises about 500 mg to about 1000 mg of efgartigimod. In an embodiment, the unit dosage form comprises about 1000 mg to about 1500 mg of efgartigimod. In an embodiment, the unit dosage form comprises about
  • the unit dosage form comprises about 1500 mg to about 2000 mg of efgartigimod.
  • the unit dosage form comprises about 500 mg of efgartigimod. In an embodiment, the unit dosage form comprises about 750 mg of efgartigimod. In an embodiment, the unit dosage form comprises about 1000 mg of efgartigimod. In an embodiment, the unit dosage form comprises about 1250 mg of efgartigimod. In an embodiment, the unit dosage form comprises about 1500 mg of efgartigimod. In an embodiment, the unit dosage form comprises about 1750 mg of efgartigimod. In an embodiment, the unit dosage form comprises about 2000 mg of efgartigimod. In an embodiment, the unit dosage form comprises about 2250 mg of efgartigimod. In an embodiment, the unit dosage form comprises about 2500 mg of efgartigimod.
  • the unit dosage form comprises about 500 mg of efgartigimod and about 2000 U/mL of rHuPH20. In an embodiment, the unit dosage form comprises about 750 mg of efgartigimod and about 2000 U/mL of rHuPH20. In an embodiment, the unit dosage form comprises about 1000 mg of efgartigimod and about 2000 U/mL of rHuPH20. In an embodiment, the unit dosage form comprises about 1250 mg of efgartigimod and about 2000 U/mL of rHuPH20. In an embodiment, the unit dosage form comprises about 1500 mg of efgartigimod and about 2000 U/mL of rHuPH20.
  • the unit dosage form comprises about 1750 mg of efgartigimod and about 2000 U/mL of rHuPH20. In an embodiment, the unit dosage form comprises about 2000 mg of efgartigimod and about 2000 U/mL of rHuPH20. In an embodiment, the unit dosage form comprises about 2250 mg of efgartigimod and about 2000 U/mL of rHuPH20. In an embodiment, the unit dosage form comprises about 2500 mg of efgartigimod and about 2000 U/mL of rHuPH20.
  • the unit dosage form comprises about 500 mg of efgartigimod and about 1000 U/mL to about 3000 U/mL of rHuPH20. In an embodiment, the unit dosage form comprises about 750 mg of efgartigimod and about 1000 U/mL to about 3000 U/mL of rHuPH20. In an embodiment, the unit dosage form comprises about 1000 mg of efgartigimod and about 1000 U/mL to about 3000 U/mL of rHuPH20. In an embodiment, the unit dosage form comprises about 1250 mg of efgartigimod and about 1000 U/mL to about 3000 U/mL of rHuPH20.
  • the unit dosage form comprises about 1500 mg of efgartigimod and about 1000 U/mL to about 3000 U/mL of rHuPH20. In an embodiment, the unit dosage form comprises about 1750 mg of efgartigimod and about 1000 U/mL to about 3000 U/mL of rHuPH20. In an embodiment, the unit dosage form comprises about 2000 mg of efgartigimod and about 1000 U/mL to about 3000 U/mL of rHuPH20. In an embodiment, the unit dosage form comprises about 2250 mg of efgartigimod and about 1000 U/mL to about 3000 U/mL of rHuPH20. In an embodiment, the unit dosage form comprises about 2500 mg of efgartigimod and about 1000 U/mL to about 3000 U/mL of rHuPH20.
  • the unit dosage form comprises the antibody molecule as a dry formulation for dissolution such as a lyophilized powder, freeze-dried powder, or water free concentrate.
  • the dry formulation is comprised in a hermetically sealed container such as a vial, an ampoule, or a sachet.
  • the unit dosage form comprises the antibody molecule as a liquid formulation, e.g., injection or infusion solution.
  • the liquid formulation is comprised in a hermetically sealed container such as a vial, a sachet, a pre-filled syringe, a pre-filled autoinjector, or a cartridge for a reusable syringe or applicator.
  • the unit dosage per vial may contain 0.5 ml, 1 ml, 2 ml, 3 ml, 4 ml, 5 ml, 6 ml, 7 ml, 8 ml, 9 ml, 10 ml, 15 ml, or 20 ml of an antibody molecule ranging from about 500 to about 2500 mg or from about 1000 mg to about 2000 mg.
  • these preparations can be adjusted to a desired concentration by adding a sterile diluent to each vial.
  • compositions disclosed herein include bulk drug compositions useful in the manufacture of pharmaceutical compositions (e.g., compositions that are suitable for administration to a subject or patient) which can be used in the preparation of unit dosage forms.
  • a composition of the invention is a pharmaceutical composition.
  • Such compositions comprise a prophylactically or therapeutically effective amount of one or more prophylactic or therapeutic agents (e.g., an antibody molecule of the invention or other prophylactic or therapeutic agent), and a pharmaceutically acceptable carrier.
  • the pharmaceutical compositions are formulated to be suitable for subcutaneous administration to a subject. Soluble Hyaluronidases
  • Soluble hyaluronidases include any, that, upon expression and secretion from a cell, exist in soluble form.
  • Such soluble hyaluronidases include, but are not limited to, non-human soluble hyaluronidases, bacterial soluble hyaluronidases, bovine PH20, ovine PH20, and variants thereof. Included among the soluble hyaluronidases are human PH20 polypeptides that have been been modified to be soluble.
  • hyaluronidases such as human PH20, that contain a glycophophatidylinositoal (GPI) anchor can be made soluble by truncation of and removal of all or a portion of the GPI anchor.
  • the human hyaluronidase PH20 which is normally membrane anchored via a GPI anchor, is made soluble by truncation of and removal of all or a portion of the GPI anchor at the C-terminus.
  • Soluble hyaluronidases also include neutral active hyaluronidases, such as the soluble human PH20 polypeptides.
  • the hyaluronidase for use in the compositions, unit dosage forms, and methods herein is a soluble neutral active hyaluronidase.
  • Exemplary hyaluronidases include a soluble form of a PH20 from any species, such as a soluble form of a PH20 of any of SEQ ID NOs: 5- 40, and such as the soluble PH20 polypeptides set forth in SEQ ID NOs. 5 and 18-23.
  • Such soluble forms include truncated forms thereof lacking all or a portion of the C-terminal GPI anchor, so long as the hyaluronidase is soluble (secreted upon expression) and retains hyaluronidase activity. Such forms also typically are mature forms that, when expressed in a cell, lack the signal peptide. Also included among soluble hyaluronidases are soluble forms of variants of any of the PH20s from any species set forth in SEQ ID NOs: 5-40 that exhibit hyaluronidase activity.
  • Variants include polypeptides having at least 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to any of SEQ ID NOs: 5-40.
  • Amino acid variants include conservative and non-conservative mutations. It is understood that residues that are important or otherwise required for the activity of a hyaluronidase, such as any described above or known to skill in the art, are generally invariant and cannot be changed. These include, for example, active site residues.
  • amino acid residues 111, 113 and 176 (corresponding to residues in the mature PH20 polypeptide set forth in SEQ ID NO: 5) of a human PH20 polypeptide, or soluble form thereof, are generally invariant and are not altered.
  • Other residues that confer glycosylation and formation of disulfide bonds required for proper folding also can be invariant.
  • the soluble hyaluronidase is normally GPI-anchored (such as, for example, human PH20) and is rendered soluble by truncation at the C-terminus. Such truncation can remove all of the GPI anchor attachment signal sequence, or can remove only some of the GPI anchor attachment signal sequence. The resulting polypeptide, however, is soluble. In instances where the soluble hyaluronidase retains a portion of the GPI anchor attachment signal sequence, 1, 2, 3, 4, 5, 6, 7 or more amino acid residues in the GPI anchor attachment signal sequence can be retained, provided the polypeptide is soluble.
  • Polypeptides containing one or more amino acids of the GPI anchor are termed extended soluble hyaluronidases.
  • One of skill in the art can determine whether a polypeptide is GPI-anchored using methods well known in the art. Such methods include, but are not limited to, using known algorithms to predict the presence and location of the GPI anchor attachment signal sequence and co-site, and performing solubility analyses before and after digestion with phosphatidylinositol-specific phospholipase C (PI-PLC) or D (PI-PLD).
  • PI-PLC phosphatidylinositol-specific phospholipase C
  • PI-PLD phosphatidylinositol-specific phospholipase C
  • Extended soluble hyaluronidases such as those set forth in SEQ ID NOs: 42- 47, can be produced by making C-terminal truncations to any naturally GPI-anchored hyaluronidase such that the resulting polypeptide is soluble and contains one or more amino acid residues from the GPI anchor attachment signal sequence (see, e.g., U.S. Patent No. 8,927,249).
  • hyaluronidases that are neutral active, soluble, contain amino acid substitutions, and have at least 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95% or more sequence identity to any of SEQ ID NOs: 42-47.
  • a soluble human hyaluronidase such as a soluble human PH20
  • Hyaluronidases used in the methods herein can be recombinantly produced or can be purified or partially-purified from natural sources, such as, for example, from testes extracts. Methods for production of recombinant proteins, including recombinant hyaluronidases, are well known in the art.
  • An exemplary soluble hyaluronidase is soluble human PH20.
  • Soluble forms of recombinant human PH20 have been produced and can be used in the compositions, combinations and methods described herein. The description of and production of such soluble forms of PH20 is described, for example, in U.S. Patent Nos. 7,767,429, 8,202,517, 8,431,380, 8,431,124, 8,450,470 8,765,685, 8,772,246, 7,871,607, 7,846,431, 7,829,081, 8,105,586, 8,187,855, 8,257,699, 8,580,252, 9,677,061, and 9,677,062 which are incorporated by reference herein.
  • soluble forms of human PH20 have been generated and can be used in the compositions, combinations and methods provided herein.
  • soluble forms include, but are not limited to, C- terminal truncated polypeptides of human PH20 set forth in SEQ ID NO: 4 having a C-terminal amino acid residue 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499 or 500 of the sequence of amino acids set forth in SEQ ID NO: 4, or polypeptides that exhibit at least 85%, 90%, 91%, 92%, 93%, 94%,
  • Soluble forms of human PH20 generally include those that contain amino acids 36-464 set forth in SEQ ID NO: 4.
  • the 35 amino acid N-terminal signal sequence is cleaved during processing, and the mature form of the protein is secreted.
  • the mature soluble polypeptides include those that contain amino acids 36 to 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482 and 483 of SEQ ID NO: 4.
  • soluble hyaluronidases are soluble human PH20 polypeptides that are 442, 443, 444, 445, 446 or 447 amino acids in length, such as set forth in any of SEQ ID NOs: 5 and 18-23 and variants thereof that have, for example, at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to a sequence of amino acids set forth in any of SEQ ID NOs: 5 and 18-23 and retains hyaluronidase activity.
  • the generation of such soluble forms of recombinant human PH20 are described, for example, in U.S. Patent Nos.
  • PH20 Generally soluble forms of PH20 are produced using protein expression systems that facilitate correct N-glycosylation to ensure the polypeptide retains activity, since glycosylation is important for the catalytic activity and stability of hyaluronidases.
  • Such cells include, for example Chinese Hamster Ovary (CHO) cells (e.g. DG44 CHO cells).
  • rHuPH20 refers to the composition produced upon expression in a cell, such as a CHO cell, of nucleic acid encoding residues 36-482 of SEQ ID NO: 4, generally linked to the native or a heterologous signal sequence (residues 1-35 of SEQ ID NO: 4).
  • rHuPH20 is produced by expression of a nucleic acid molecule, such as encoding amino acids 1-482 (set forth in SEQ ID NO: 4). Post translational processing removes the 35 amino acid signal sequence, leaving a polypeptide or a mixture of polypetides, including those set forth in SEQ ID NOs: 5 and 18-23.
  • rHuPH20 As produced in the culture medium there is heterogeneity at the C- terminus such that the product, designated rHuPH20, includes a mixture of species that can include any one or more of SEQ ID NOs: 5 and 18-23 in various abundance.
  • rHuPH20 is produced in cells that facilitate correct N-glycosylation to retain activity, such as CHO cells (e.g. DG44 CHO cells).
  • CHO cells e.g. DG44 CHO cells
  • the most abundant species is the 446 amino acid polypeptide corresponding to residues 36-481 of SEQ ID NO: 4.
  • Glycosylation, including N- and O-linked glycosylation, of some hyaluronidases, including the soluble PH20 hyaluronidases, can be important for their catalytic activity and stability.
  • removal of N-linked glycosylation can result in near complete inactivation of the hyaluronidase activity.
  • the presence of N-linked glycans can be important for generating an active enzyme.
  • N-linked oligosaccharides fall into several primary types (oligomannose, complex, hybrid, sulfated), all of which have (Man) 3-GlcNAc-GlcNAc- cores attached via the amide nitrogen of Asn residues that fall within -Asn-Xaa-Thr/Ser-sequences (where Xaa is not Pro). Glycosylation at an -Asn-Xaa-Cys-site has been reported for coagulation protein C.
  • a hyaluronidase such as a PH20 hyaluronidase, can contain N-glycosidic and O-glycosidic linkages.
  • PH20 has O-linked oligosaccharides as well as N-linked oligosaccharides. There are six potential N-linked glycosylation sites at N82, N166, N235, N254, N368, N393 of human PH20 exemplified in SEQ ID NO: 1.
  • unit dosage forms of a biologic that are determined based on a modeling approach, which matches a pharmacodynamic (PD) value of the SC dose with that of a known reference IV dose, while a pharmacokinetic (PK) value of the SC dose is less than that of the IV dose.
  • the unit dosage forms provided herein show comparable safety and efficacy as compared to a reference IV dose, and are therefore, non-inferior to the IV dose, providing patients with a more convenient alternative method of administration of a biologic.
  • Non-limiting examples of biologies that are useful in the unit dosage forms provided herein include antibodies, antibody fragments, anticoagulants, blood factors, bone morphogenetic proteins, enzymes, fusion proteins, growth factors, hormones, interferons, interleukins, and thrombolytics.
  • Further non-limiting examples of biologies that are useful in the unit dosage forms provided herein include any biologic for which there is a biomarker that can be used to determine appropriate subcutaneous dosing of the biologic, e.g., IgG levels can be used to determine subcutaneous dosing of an FcRn antagonist.
  • the biomarker is present in healthy subjects and/or test animals, such that analysis in healthy volunteers or test animals can be used to determine subcutaneous dosing of the biologic.
  • the biologic antagonizes FcRn binding to an antibody Fc region.
  • the biologic is an antibody, for example, an anti-FcRn antibody. Any anti-FcRn antibody is suitable for use in the unit dosage forms disclosed herein.
  • the antibody is rozanolixizumab (UCB7665), nipocalimab (M281), orilanolimab (AEXN1830/SYNT001), or batoclimab (IMVT-1401/RVT1401/HBM9161).
  • the biologic comprises or consists of a variant Fc region, or FcRn binding fragment thereof, which binds to FcRn with a higher affinity at pH5.5 as compared to a corresponding wild-type Fc region.
  • the variant Fc region, or FcRn binding fragment thereof consists of two Fc domains.
  • the amino acid sequence of the Fc domains of the variant Fc region comprises the amino acid sequence of SEQ ID NO: 1.
  • the amino acid sequence of the Fc domains of the variant Fc region consists of the amino acid sequence of SEQ ID NO: 1.
  • the amino acid sequence of the Fc domains of the variant Fc region comprises the amino acid sequence of SEQ ID NO: 2.
  • the amino acid sequence of the Fc domains of the variant Fc region consists of the amino acid sequence of SEQ ID NO: 2.
  • the amino acid sequence of the Fc domains of the variant Fc region comprises the amino acid sequence of SEQ ID NO: 3. In an embodiment, the amino acid sequence of the Fc domains of the variant Fc region consists of the amino acid sequence of SEQ ID NO: 3.
  • the isolated FcRn antagonist consists of a variant Fc region, wherein the variant Fc region consists of two Fc domains which form a homodimer, wherein the amino acid sequence of each of the Fc domains consists of SEQ ID NO: 1.
  • the isolated FcRn antagonist consists of a variant Fc region, wherein the variant Fc region consists of two Fc domains which form a homodimer, wherein the amino acid sequence of each of the Fc domains consists of SEQ ID NO: 2.
  • the isolated FcRn antagonist consists of a variant Fc region, wherein the variant Fc region consists of two Fc domains which form a homodimer, wherein the amino acid sequence of each of the Fc domains consists of SEQ ID NO: 3.
  • the biologic is efgartigimod (CAS Registry No. 1821402- 21-4).
  • the instant disclosure provides a method of treating a disease or disorder comprising subcutaneously administering a unit dosage form of a biologic disclosed herein, to a subject in need thereof.
  • the instant disclosure provides a method of treating an antibody-mediated autoimmune disease comprising subcutaneously administering a unit dosage form of a variant Fc region disclosed herein, or FcRn binding fragment thereof, to a subject in need thereof.
  • the autoimmune disease is selected from the group consisting of allogenic islet graft rejection, alopecia areata, ankylosing spondylitis, antiphospholipid syndrome, autoimmune Addison’s disease, Alzheimer’s disease, antineutrophil cytoplasmic autoantibodies (ANCA), autoimmune diseases of the adrenal gland, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune myocarditis, autoimmune neutropenia, autoimmune oophoritis and orchitis, immune thrombocytopenia (ITP or idiopathic thrombocytopenic purpura or idiopathic thrombocytopenia purpura or immune mediated thrombocytopenia), autoimmune urticaria, Behcet’s disease, bullous pemphigoid (BP), cardiomyopathy, Castleman’s syndrome, celiac spruce-dermatitis, chronic fatigue immune disfunction syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP
  • the variant Fc region, or FcRn binding fragment thereof is administered once weekly. In an embodiment, the variant Fc region, or FcRn binding fragment thereof, is administered once every two weeks. In an embodiment, the variant Fc region, or FcRn binding fragment thereof, is administered once every 10-14 days. In an embodiment, the variant Fc region, or FcRn binding fragment thereof, is administered once every three weeks. In an embodiment, the variant Fc region, or FcRn binding fragment thereof, is administered once every four weeks.
  • the dose of the variant Fc region, or FcRn binding fragment thereof is about 950 mg, about 975 mg, about 1000 mg, about 1025 mg, or about 1050 mg. In an embodiment, the dose of the variant Fc region, or FcRn binding fragment thereof, is about 950 mg. In an embodiment, the dose of the variant Fc region, or FcRn binding fragment thereof, is about 975 mg. In an embodiment, the dose of the variant Fc region, or FcRn binding fragment thereof, is about 1000 mg. In an embodiment, the dose of the variant Fc region, or FcRn binding fragment thereof, is about 1025 mg. In an embodiment, the dose of the variant Fc region, or FcRn binding fragment thereof, is about 1050 mg.
  • the variant Fc region, or FcRn binding fragment thereof is administered once weekly.
  • the weekly dose is about 950 mg, about 975 mg, about 1000 mg, about 1025 mg, or about 1050 mg.
  • the weekly dose is about 950 mg.
  • the weekly dose is about 975 mg.
  • the weekly dose is about 1000 mg.
  • the weekly dose is about 1025 mg.
  • the weekly dose is about 1050 mg.
  • the treatment comprises at least 2 weekly doses. In an embodiment, the treatment comprises at least 3 weekly doses. In an embodiment, the treatment comprises at least 4 weekly doses. In an embodiment, the treatment comprises at least 5 weekly doses. In an embodiment, the treatment comprises at least 6 weekly doses. In an embodiment, the treatment comprises at least 7 weekly doses. In an embodiment, the treatment comprises at least 8 weekly doses. In an embodiment, the treatment comprises at more than 8 weekly doses.
  • the dose is an injection. In an embodiment, the dose is a unit dosage form.
  • the variant Fc region, or FcRn binding fragment thereof is administered with a recombinant enzyme human hyaluronidase.
  • the recombinant enzyme human hyaluronidase is rHuPH20.
  • the recombinant enzyme human hyaluronidase and the variant Fc region, or FcRn binding fragment thereof are contained in the same formulation.
  • the recombinant enzyme human hyaluronidase and the variant Fc region, or FcRn binding fragment thereof are contained in the separate formulations.
  • efgartigimod is administered with a recombinant enzyme human hyaluronidase.
  • the recombinant enzyme human hyaluronidase is rHuPH20.
  • the recombinant enzyme human hyaluronidase and efgartigimod are contained in the same formulation.
  • the recombinant enzyme human hyaluronidase and efgartigimod are contained in the separate formulations.
  • a total serum IgG reduction in the patient of about 60% compared to baseline IgG level is obtained. In an embodiment, a total serum IgG reduction in the patient of about 65%, about 70%, about 75%, or about 80% compared to baseline IgG level is obtained. In an embodiment, a total serum IgG reduction in the patient of about 65% compared to baseline IgG level is obtained. In an embodiment, a total serum IgG reduction in the patient of about 70% compared to baseline IgG level is obtained. In an embodiment, a total serum IgG reduction in the patient of about 75% compared to baseline IgG level is obtained. In an embodiment, a total serum IgG reduction in the patient of about 80% compared to baseline IgG level is obtained.
  • the percentage of total serum IgG reduction in the patient is achieved within 1 month from the first dose. In an embodiment, the percentage of total serum IgG reduction in the patient is achieved within 2 weeks, 3 weeks, 4 weeks, 5 weeks, or 6 weeks from the first dose. In an embodiment, the percentage of total serum IgG reduction in the patient is achieved within 2 weeks from the first dose. In an embodiment, the percentage of total serum IgG reduction in the patient is achieved within 3 weeks from the first dose. In an embodiment, the percentage of total serum IgG reduction in the patient is achieved within 4 weeks from the first dose. In an embodiment, the percentage of total serum IgG reduction in the patient is achieved within 5 weeks from the first dose. In an embodiment, the percentage of total serum IgG reduction in the patient is achieved within 6 weeks from the first dose. In an embodiment, the percentage of total serum IgG reduction in the patient is achieved within 31, 30, 29, 28, 27, 26, or 25 days from the first dose.
  • the maximum percentage of total serum IgG reduction in the patient is achieved within 1 month from the first dose. In an embodiment, the maximum percentage of total serum IgG reduction in the patient is achieved within 2 weeks, 3 weeks, 4 weeks, 5 weeks, or 6 weeks from the first dose. In an embodiment, the maximum percentage of total serum IgG reduction in the patient is achieved within 2 weeks from the first dose. In an embodiment, the maximum percentage of total serum IgG reduction in the patient is achieved within 3 weeks from the first dose. In an embodiment, the maximum percentage of total serum IgG reduction in the patient is achieved within 4 weeks from the first dose. In an embodiment, the maximum percentage of total serum IgG reduction in the patient is achieved within 5 weeks from the first dose. In an embodiment, the maximum percentage of total serum IgG reduction in the patient is achieved within 6 weeks from the first dose. In an embodiment, the maximum percentage of total serum IgG reduction in the patient is achieved within 31, 30, 29, 28, 27, 26, or 25 days from the first dose.
  • the total serum IgG level in the patient is reduced to 2000 to
  • the total serum IgG level in the patient is reduced to 2000 to
  • the total serum IgG level in the patient is reduced to 3000 to
  • the total serum IgG level in the patient is reduced to 2500 to
  • the total serum IgG level in the patient is reduced to 2750 to
  • the total serum IgG in the patient is analyzed using a bioanalytical method. In an embodiment, the total serum IgG in the patient is analyzed using
  • the total serum IgG in the patient is analyzed using ELISA. In an embodiment, the total serum IgG in the patient is analyzed using automated diagnostic analyzer (IVD).
  • At least one of the IgG subtypes is reduced.
  • IgGl is reduced.
  • IgG2 is reduced.
  • IgG3 is reduced.
  • IgG4 is reduced.
  • the variant Fc region is efgartigimod.
  • a variant Fc region, or FcRn binding fragment thereof wherein the Fc domains of the Fc region comprise the amino acids Y, T, E, K, F, and Y at EU Kabat positions 252, 254, 256, 433, 434, and 436 respectively, for use in treating myasthenia gravis in a human patient.
  • the instant disclosure provides a variant Fc region, or FcRn binding fragment thereof, wherein the Fc domains of the Fc region comprise the amino acids Y, T, E, K, F, and Y at EU Kabat positions 252, 254, 256, 433, 434, and 436 respectively, for use in treating myasthenia gravis in a human patient, wherein: the variant Fc region, or FcRn binding fragment thereof, is administered subcutaneously at a weekly dose of between 950 and 1050 mg, independent of the weight of the patient, and a total serum IgG reduction in the patient of at least 60% compared to baseline IgG level is obtained.
  • the weekly dose is about 950 mg, about 975 mg, about 1000 mg, about 1025 mg, or about 1050 mg. In an embodiment, the weekly dose is about 950 mg. In an embodiment, the weekly dose is about 975 mg. In an embodiment, the weekly dose is about 1000 mg. In an embodiment, the weekly dose is about 1025 mg. In an embodiment, the weekly dose is about 1050 mg.
  • the treatment comprises at least 2 weekly doses. In an embodiment, the treatment comprises at least 3 weekly doses. In an embodiment, the treatment comprises at least 4 weekly doses. In an embodiment, the treatment comprises at least 5 weekly doses. In an embodiment, the treatment comprises at least 6 weekly doses. In an embodiment, the treatment comprises at least 7 weekly doses. In an embodiment, the treatment comprises at least 8 weekly doses. In an embodiment, the treatment comprises at more than 8 weekly doses.
  • the dose is an injection. In an embodiment, the dose is a unit dosage form.
  • the variant Fc region, or FcRn binding fragment thereof is administered with a recombinant enzyme human hyaluronidase.
  • the recombinant enzyme human hyaluronidase is rHuPH20.
  • the recombinant enzyme human hyaluronidase and the variant Fc region, or FcRn binding fragment thereof are contained in the same formulation.
  • the recombinant enzyme human hyaluronidase and the variant Fc region, or FcRn binding fragment thereof are contained in the separate formulations.
  • the recombinant enzyme human hyaluronidase and the variant Fc region, or FcRn binding fragment thereof are co-administered. In an embodiment, the recombinant enzyme human hyaluronidase and the variant Fc region, or FcRn binding fragment thereof, are administered sequentially. In an embodiment, the recombinant enzyme human hyaluronidase is administered before the variant Fc region, or FcRn binding fragment thereof. In an embodiment, the recombinant enzyme human hyaluronidase is administered after the variant Fc region, or FcRn binding fragment thereof.
  • efgartigimod is administered with a recombinant enzyme human hyaluronidase.
  • the recombinant enzyme human hyaluronidase is rHuPH20.
  • the recombinant enzyme human hyaluronidase and efgartigimod are contained in the same formulation.
  • the recombinant enzyme human hyaluronidase and efgartigimod are contained in the separate formulations.
  • the recombinant enzyme human hyaluronidase and efgartigimod are co-administered.
  • the recombinant enzyme human hyaluronidase and efgartigimod are administered sequentially. In an embodiment, the recombinant enzyme human hyaluronidase is administered before efgartigimod. In an embodiment, the recombinant enzyme human hyaluronidase is administered after efgartigimod.
  • a total serum IgG reduction in the patient of about 60% compared to baseline IgG level is obtained. In an embodiment, a total serum IgG reduction in the patient of about 65%, about 70%, about 75%, or about 80% compared to baseline IgG level is obtained. In an embodiment, a total serum IgG reduction in the patient of about 65% compared to baseline IgG level is obtained. In an embodiment, a total serum IgG reduction in the patient of about 70% compared to baseline IgG level is obtained. In an embodiment, a total serum IgG reduction in the patient of about 75% compared to baseline IgG level is obtained. In an embodiment, a total serum IgG reduction in the patient of about 80% compared to baseline IgG level is obtained.
  • the percentage of total serum IgG reduction in the patient is achieved within 1 month from the first dose. In an embodiment, the percentage of total serum IgG reduction in the patient is achieved within 2 weeks, 3 weeks, 4 weeks, 5 weeks, or 6 weeks from the first dose. In an embodiment, the percentage of total serum IgG reduction in the patient is achieved within 2 weeks from the first dose. In an embodiment, the percentage of total serum IgG reduction in the patient is achieved within 3 weeks from the first dose. In an embodiment, the percentage of total serum IgG reduction in the patient is achieved within 4 weeks from the first dose. In an embodiment, the percentage of total serum IgG reduction in the patient is achieved within 5 weeks from the first dose.
  • the percentage of total serum IgG reduction in the patient is achieved within 6 weeks from the first dose. In an embodiment, the percentage of total serum IgG reduction in the patient is achieved within 31, 30, 29, 28, 27, 26, or 25 days from the first dose. [00186] In an embodiment, the maximum percentage of total serum IgG reduction in the patient is achieved within 1 month from the first dose. In an embodiment, the maximum percentage of total serum IgG reduction in the patient is achieved within 2 weeks, 3 weeks, 4 weeks, 5 weeks, or 6 weeks from the first dose. In an embodiment, the maximum percentage of total serum IgG reduction in the patient is achieved within 2 weeks from the first dose. In an embodiment, the maximum percentage of total serum IgG reduction in the patient is achieved within 3 weeks from the first dose.
  • the maximum percentage of total serum IgG reduction in the patient is achieved within 4 weeks from the first dose. In an embodiment, the maximum percentage of total serum IgG reduction in the patient is achieved within 5 weeks from the first dose. In an embodiment, the maximum percentage of total serum
  • IgG reduction in the patient is achieved within 6 weeks from the first dose.
  • the maximum percentage of total serum IgG reduction in the patient is achieved within 31, 30, 29, 28, 27, 26, or 25 days from the first dose.
  • the total serum IgG level in the patient is reduced to 2000 to
  • the total serum IgG level in the patient is reduced to 2000 to
  • the total serum IgG level in the patient is reduced to 3000 to
  • the total serum IgG level in the patient is reduced to 2500 to
  • the total serum IgG level in the patient is reduced to 2750 to
  • the total serum IgG in the patient is analyzed using a bioanalytical method. In an embodiment, the total serum IgG in the patient is analyzed using ELISA or automated diagnostic analyzer (IVD). In an embodiment, the total serum IgG in the patient is analyzed using ELISA. In an embodiment, the total serum IgG in the patient is analyzed using automated diagnostic analyzer (IVD).
  • At least one of the IgG subtypes is reduced.
  • IgGl is reduced.
  • IgG2 is reduced.
  • IgG3 is reduced.
  • IgG4 is reduced.
  • the variant Fc region is efgartigimod.
  • Fc region or FcRn binding fragment thereof, wherein the Fc domains of the Fc region comprise the amino acids Y, T, E, K, F, and Y at EU Kabat positions 252, 254, 256, 433, 434, and 436 respectively, for use in treating pemphigus vulgaris in a human patient.
  • the instant disclosure provides a variant Fc region, or FcRn binding fragment thereof, wherein the Fc domains of the Fc region comprise the amino acids Y, T, E, K, F, and Y at EU Kabat positions 252, 254, 256, 433, 434, and 436 respectively, for use in treating pemphigus vulgaris in a human patient, wherein: the variant Fc region, or FcRn binding fragment thereof, is administered subcutaneously at a weekly dose of between 1950 and 2050 mg, independent of the weight of the patient, and a total serum IgG reduction in the patient of at least 60% compared to baseline IgG level is obtained.
  • the weekly dose is about 1950 mg, about 1975 mg, about 2000 mg, about 2025 mg, or about 2050 mg. In an embodiment, the weekly dose is about 1950 mg. In an embodiment, the weekly dose is about 1975 mg. In an embodiment, the weekly dose is about 2000 mg. In an embodiment, the weekly dose is about 2025 mg. In an embodiment, the weekly dose is about 2050 mg.
  • the treatment comprises at least 2 weekly doses. In an embodiment, the treatment comprises at least 3 weekly doses. In an embodiment, the treatment comprises at least 4 weekly doses. In an embodiment, the treatment comprises at least 5 weekly doses. In an embodiment, the treatment comprises at least 6 weekly doses. In an embodiment, the treatment comprises at least 7 weekly doses. In an embodiment, the treatment comprises at least 8 weekly doses. In an embodiment, the treatment comprises at more than 8 weekly doses.
  • the dose is a unit dosage form.
  • the variant Fc region, or FcRn binding fragment thereof is administered with a recombinant enzyme human hyaluronidase.
  • the recombinant enzyme human hyaluronidase is rHuPH20.
  • the recombinant enzyme human hyaluronidase and the variant Fc region, or FcRn binding fragment thereof are contained in the same formulation.
  • the recombinant enzyme human hyaluronidase and the variant Fc region, or FcRn binding fragment thereof are contained in the separate formulations.
  • efgartigimod is administered with a recombinant enzyme human hyaluronidase.
  • the recombinant enzyme human hyaluronidase is rHuPH20.
  • the recombinant enzyme human hyaluronidase and efgartigimod are contained in the same formulation.
  • the recombinant enzyme human hyaluronidase and efgartigimod are contained in the separate formulations.
  • a total serum IgG reduction in the patient of about 60% compared to baseline IgG level is obtained. In an embodiment, a total serum IgG reduction in the patient of about 65%, about 70%, about 75%, or about 80% compared to baseline IgG level is obtained. In an embodiment, a total serum IgG reduction in the patient of about 65% compared to baseline IgG level is obtained. In an embodiment, a total serum IgG reduction in the patient of about 70% compared to baseline IgG level is obtained. In an embodiment, a total serum IgG reduction in the patient of about 75% compared to baseline IgG level is obtained. In an embodiment, a total serum IgG reduction in the patient of about 80% compared to baseline IgG level is obtained.
  • the percentage of total serum IgG reduction in the patient is achieved within 1 month from the first dose. In an embodiment, the percentage of total serum IgG reduction in the patient is achieved within 2 weeks, 3 weeks, 4 weeks, 5 weeks, or 6 weeks from the first dose. In an embodiment, the percentage of total serum IgG reduction in the patient is achieved within 2 weeks from the first dose. In an embodiment, the percentage of total serum IgG reduction in the patient is achieved within 3 weeks from the first dose. In an embodiment, the percentage of total serum IgG reduction in the patient is achieved within 4 weeks from the first dose. In an embodiment, the percentage of total serum IgG reduction in the patient is achieved within 5 weeks from the first dose. In an embodiment, the percentage of total serum IgG reduction in the patient is achieved within 6 weeks from the first dose.
  • the maximum percentage of total serum IgG reduction in the patient is achieved within 1 month from the first dose. In an embodiment, the maximum percentage of total serum IgG reduction in the patient is achieved within 2 weeks, 3 weeks, 4 weeks, 5 weeks, or 6 weeks from the first dose. In an embodiment, the maximum percentage of total serum IgG reduction in the patient is achieved within 2 weeks from the first dose. In an embodiment, the maximum percentage of total serum IgG reduction in the patient is achieved within 3 weeks from the first dose. In an embodiment, the maximum percentage of total serum IgG reduction in the patient is achieved within 4 weeks from the first dose. In an embodiment, the maximum percentage of total serum IgG reduction in the patient is achieved within 5 weeks from the first dose. In an embodiment, the maximum percentage of total serum IgG reduction in the patient is achieved within 6 weeks from the first dose.
  • the total serum IgG level in the patient is reduced to 2000 to 4000 pg/mL. In an embodiment, the total serum IgG level in the patient is reduced to 2000 to 3000 pg/mL. In an embodiment, the total serum IgG level in the patient is reduced to 3000 to 4000 pg/mL. In an embodiment, the total serum IgG level in the patient is reduced to 2500 to 3500 pg/mL. In an embodiment, the total serum IgG level in the patient is reduced to 2750 to 3250 pg/mL.
  • the total serum IgG in the patient is analyzed using a bioanalytical method. In an embodiment, the total serum IgG in the patient is analyzed using ELISA or automated diagnostic analyzer (IVD). In an embodiment, the total serum IgG in the patient is analyzed using ELISA. In an embodiment, the total serum IgG in the patient is analyzed using automated diagnostic analyzer (IVD).
  • At least one of the IgG subtypes is reduced.
  • IgGl is reduced.
  • IgG2 is reduced.
  • IgG3 is reduced.
  • IgG4 is reduced.
  • the variant Fc region is efgartigimod.
  • Example 1 Study comparing the PK/PD and safety of subcutaneous doses of efgartigimod + rHuPH20
  • Efgartigimod (UNII: 961YV2O515) is a human IgGl-derived Fc fragment of the za allotype (a variant Fc region) that binds with nanomolar affinity to human FcRn.
  • PK pharmacokinetic
  • PD pharmacodynamic
  • An SC formulation with recombinant human hyaluronidase PH20 enzyme has been developed for SC administration of efgartigimod as an alternative to IV infusion.
  • the enzyme rHuPH20 locally degrades hyaluronan (HA) in the SC space, which allows for increased dispersion and absorption of co-administered therapies.
  • the ready-to-use liquid SC formulation comprising efgartigimod and rHuPH20 (efgartigimod-PH20) was injected as a fixed dose. This formulation and method of administration are expected to increase patient convenience compared to the IV formulation and administration.
  • Treatment A single SC dose of 750 mg efgartigimod co-administered with 2000 U/mL the hyaluronidase enzyme, rHuPH20; b.
  • Treatment B single SC dose of 1250 mg efgartigimod co-administered with 2000 U/mL rHuPH20; c.
  • Treatment C single SC dose of 1750 mg efgartigimod co-administered with 2000 U/mL rHuPH20; and d.
  • Treatment D single SC dose of 10 mg/kg efgartigimod co-administered with 2000 U/mL rHuPH20. Analysis of Pharmacokinetic Parameters
  • Plasma concentrations of efgartigimod at each sampling time point were analyzed by the following summary statistics: arithmetic mean calculated using untransformed data, standard deviation (SD) calculated using untransformed data, minimum, median, maximum, number of observations, and number of observations > lower limit of quantification (LLOQ).
  • SD standard deviation
  • Example 2 Calculation of subcutaneous dose of efgartigimod from pharmacokinetic (PK) and pharmacodynamic (PD) data
  • PK/PD modeling was used to match reduction of total IgG (a PD parameter) of an IV and SC dose of a biologic, based on data from single SC administrations of the biologic, using a known IV dose as a benchmark.
  • a previously determined PK/PD model was used to construct simulations of total IgG reduction following different subcutaneous doses of efgartigimod, with and without the hyaluronidase enzyme rHuPH20.
  • the PK/PD model was used to describe the Cmax and the AUC, with or without rHuPH20, and the median trend of IgG reduction across dose groups.
  • the final PK model consisted of a three-compartmental model with linear clearance and it included the assumption that the second peripheral volume (V3) was equal to the first peripheral volume (V2).
  • An additive residual error model was used, which is standard for log-transformed data.
  • the focus of the analysis was the modelling of data from 32 subjects treated with a single SC injection of either 750 mg, 1250 mg, 1750 mg, or 10 mg/kg of efgartigimod + rHuPH20 (the study described in Example 1).
  • PK and IgG historical data from treatments A (10 mg/kg single IV dose) and B (10 mg/kg single SC dose) from a previous study were included in the analysis.
  • the parameters from the existing PK model for healthy volunteers were used to predict healthy volunteer data in the study described in Example 1.
  • the model did not adequately predict the PK of efgartigimod co-administered with rHuPH20, especially in the absorption phase. Therefore, the absorption-related parameters (i.e., absolute bioavailability and duration of the zero-order absorption process) were estimated for the study described in Example 1, together with the residual error. In this way, the description of the PK of efgartigimod in the new study improved. However, the absorption phase was not adequately described, yet.
  • the first-order absorption rate constant kA was also estimated (i.e., 0.24 l/h in Table 3) for the study described in Example 1, whereas, in the previous PK model, the parameter kA was fixed to 99, to resemble the zero-order absorption. In this way, a sequential zero-first-order absorption model could be identified and it improved the description of the PK of efgartigimod + rHuPH20. Further, the duration of the zero-order process was estimated to be lower in the study described in Example 1, as compared to the historical data (i.e., 83.7 h vs 131 h, as reported in Table 3).
  • the PK model adequately captured the typical profile of efgartigimod concentration as well as inter-individual variability across treatment groups in the study described in Example 1 (see Figure 3) and in the historical data (see Figure 4).
  • the effect of body weight was investigated on PK parameters, but it was not found to be statistically significant.
  • CV% 100 * standard error/Value, b 10(He“ 2 - 1 , c a) x , y /(CV%(x)-CV%(y)), d value fixed to the estimate from the combined analysis for studies efgartigimod-1501 and efgartigimod- 1901
  • the PK/total IgG model consisted of an indirect response model in which the concentration of efgartigimod stimulated the degradation rate of total IgG (k ou t). This model reflects the mechanism of action for efgartigimod, which binds the FcRn receptor and reduces recycling of total IgG and causes increased degradation of total IgG.
  • An E ma x model was used to quantify the PK/PD relationship (with the E ma x parameter fixed to the estimate from the combined analysis of previous studies) because the total IgG reduction effect of efgartigimod was found to be saturable. An effect compartment was included in the model to allow for an accurate description of the delay in decrease in total IgG concentrations. Inter-individual variability (IIV) was identified for baseline total IgG levels and for the potency (EC50) of efgartigimod assuming a log-normal distribution and residual variability was described by a proportional error model.
  • the model parameters derived from a previous combined analysis for previous efgartigimod studies were used to predict the total IgG concentration in the study described in Example 1. To do so, it was assumed that the baseline of total IgG in the study described in Example 1 was the same as the baseline in one of the previous studies (i.e., 8570 mg/L). Overall, the model could predict 750 mg, 1750 mg, and 10 mg/kg dose groups reasonably well. However, the 1250 mg treatment group was not adequately predicted. By estimating the baseline of total IgG in the study described in Example 1 , the model improved the description of total IgG across dose groups (parameter estimates are reported in Table 4).
  • the final PK/total IgG model previously developed to describe total IgG in the healthy population, consisted of an indirect response model, in which the concentration of efgartigimod stimulated the degradation rate of the biomarker of interest. This model was refined by the inclusion of an effect compartment to adequately capture the total IgG concentration and reduction in healthy volunteers treated with efgartigimod + rHuPH20 in the study described in Example 1. No body weight effect was found to be statistically significant on either PK or PD parameters.
  • RSE (%) is calculated as standard error/Value*100; %CV is calculated as sqrt(exp((o 2 )-l)*100 or sqrt(exp( ⁇ j 2 )-l)*100.
  • the median and 5th and 95th percentiles of the metrics obtained with 10 mg/kg IV of efgartigimod QW were: (a) AUECD22-D29: 949 g h/L (863 g h/L; 1030 g h/L); (b) maximum total IgG reduction after the fourth dose between day 22 and day 29: -66.59% (- 68.96%; -64.38%); and (c) trough reduction of total IgG on day 29: -65.75% (-68.43%; - 63.42%).
  • the percentage of simulated values exceeding the target level was calculated for each of the three metrics (see Figures 15, 16, and 17).
  • the 825 mg efgartigimod PH20 SC dose provided 34.2% AUECD22-D29 values above the median AUECD22-D29 obtained with the benchmark scenario, 32.8% of maximum total IgG reduction between day 22 and day 29 below the corresponding median obtained with 10 mg/kg IV of efgartigimod QW, and 46.4% of trough total IgG reduction on day 29 below the corresponding median obtained with the benchmark scenario.
  • the 900 mg efgartigimod PH20 SC dose provided 47.6% AUECD22-D29 values above the median AUECD22-D29 obtained with the benchmark scenario, 56.4% of maximum total IgG reduction between day 22 and day 29 below the corresponding median obtained with 10 mg/kg IV of efgartigimod QW, and 72.4% of trough total IgG reduction on day 29 below the corresponding median obtained with the benchmark scenario.
  • the 925 mg efgartigimod PH20 SC dose provided 51.4% AUECD22-D29 values above the median AUECD22-D29 obtained with the benchmark scenario, 65.4% of maximum total IgG reduction between day 22 and day 29 below the corresponding median obtained with 10 mg/kg IV of efgartigimod QW, and 78.4% of trough total IgG reduction on day 29 below the corresponding median obtained with the benchmark scenario.
  • a dose of 1000 mg of efgartigimod PH20 SC was selected for further clinical development because this dose was predicted to be close to the 5th percentile of the benchmark scenario for AUECD22-D29 and the 95th percentile of the benchmark scenario for the maximum total IgG reduction between day 22 and day 29 and trough total IgG reduction on day 29.
  • the simulations showed that (a) a dose of 1000 mg efgartigimod PH20 SC provided a 5th percentile of AUECD22-D29 comparable to the 5th percentile obtained with 10 mg/kg IV of efgartigimod once per week (Figure 12); (b) a dose of 950 mg efgartigimod PH20 SC provided a 95th percentile of the maximum total IgG reduction between day 22 and day 29 comparable to the 95th percentile obtained with 10 mg/kg IV of efgartigimod once per week ( Figure 13); and (c) a dose of 900 mg efgartigimod PH20 SC provided a 95th percentile of the trough total IgG reduction on day 29 comparable to the 95th percentile obtained with 10 mg/kg IV of efgartigimod once per week ( Figure 14).
  • the percentages of simulated total IgG reduction obtained with 1000 mg efgartigimod PH20 SC QW below the median of the total IgG reduction obtained with 10 mg/kg IV of efgartigimod QW were predicted to be : i) 9.6% (before the dose on day 8 is given); ii) 78.2% (before the dose on day 15 is given); iii) 92.0% (before the dose on day 22 is given); iv) 92.6% (before the dose on day 29 is given) (see Figure 20 and Table 8).
  • the 1000 mg dose of efgartigimod PH20 SC was selected for future clinical development because it was predicted to be close to the 5th percentile of the benchmark scenario for AUECD22-D29 and 95th percentile of the benchmark scenario for the maximum total IgG reduction between day 22 and day 29 and trough total IgG reduction on day 29.
  • Example 3 A study to compare the pharmacodynamics, pharmacokinetics, safety, and tolerability of multiple intravenous infusions of efgartigimod with multiple subcutaneous injections of efgartigimod-PH20 SC in healthy subjects
  • the efgartigimod IV 10 mg/kg dose selected for this study is the dose that has been shown to be well-tolerated, safe, and associated with clinical efficacy in patients with generalized myasthenia gravis.
  • the EFGARTIGIMOD-PH20 SC 1000 mg dose is predicted to result in a similar PD effect as the efgartigimod IV 10 mg/kg dose, and was chosen based on the modeling and simulations described in Example 2.
  • a total of 54 healthy subjects were randomized in a 1:1 ratio to either efgartigimod IV (27 subjects) or EFGARTIGIMOD-PH20 SC (27 subjects). The subjects were selected based on the inclusion and exclusion criteria listed below.
  • the subject is between 18 and 65 years of age, inclusive, on the day when the ICF is signed.
  • the subject is either male or female of non-childbearing potential (postmenopausal [defined by continuous amenorrhea for at least 1 year without an alternative medical cause with a follicle-stimulating hormone (FSH) of >33.4 IU/L; in subjects on hormonal replacement therapy, a historical value pretreatment of >33.4 IU/L will be accepted as proof of menopausal status]) OR have a documented permanent sterilization procedure (i.e., hysterectomy, bilateral salpingectomy, and bilateral oophorectomy).
  • FSH follicle-stimulating hormone
  • the female subject has a negative pregnancy test at day -1.
  • the subject has a body mass index (BMI) between 18 and 30 kg/m 2 , inclusively, with a weight of >50 kg and ⁇ 100 kg at screening.
  • BMI body mass index
  • the subject is able to understand the requirements of the study, provide written informed consent (including consent for the use and disclosure of research-related health information), willing and able to comply with the protocol procedures (including required study visits).
  • the subject is in good physical and mental health, per the opinion of the investigator, based on medical history, physical examination, ECG, and vital sign findings; and biochemistry, hematology, virology, and urinalysis test results prior to the first IMP administration.
  • the non-sterilized male subject who is sexually active with a female partner of childbearing potential must use effective contraception. Male subject practicing true sexual abstinence (when consistent with the preferred and usual lifestyle of the participant) can be included.
  • the sterilized male subject who has had a vasectomy with documented aspermia post procedure can be included.
  • no male subject will be allowed to donate sperm during the period from signing the ICF, throughout the duration of the trial, and 90 days after the last administration of the IMP.
  • the condition of the skin tissue on the subject’s abdomen must allow for absorption and assessment of local safety of the planned SC injection, as determined by the investigator.
  • the subject agrees to discontinue and refrain from all medications (including over the counter and/or prescription medications), except for occasional paracetamol use (maximum dose of 2 g/day and maximum of 10 g/2 weeks), antacid use, and ibuprofen use (maximum dose of 400 mg/day and not to be co-administered with antacid), at least 2 weeks before the first efgartigimod administration through the final follow-up visit on day 78.
  • the subject agrees to withhold from strenuous activities from at least 2 weeks before the first efgartigimod administration through the final follow-up visit on day 78.
  • the subject is a non-smoker and does not use any nicotine-containing products.
  • a non-smoker is defined as an individual who has abstained from smoking for at least 1 year prior to screening.
  • the subject has a negative nicotine analyte test at screening and on day -1.
  • the subject has a negative urine drug screen (amphetamines, barbiturates, benzodiazepines, cannabis, cocaine, opiates, methadone, and tricyclic antidepressants) at screening and on day -1.
  • the subject has a negative alcohol urine test at screening and on day -1.
  • the subject has a body temperature of 35.2°C to 37.6°C at screening and on day -1.
  • the subject has previously participated in clinical studies with efgartigimod and was administered efgartigimod.
  • the subject has a known hypersensitivity to 1 of the components in the efgartigimod formulation, or a history of severe allergic or anaphylactic reactions, in the opinion of the investigator.
  • the subject tests positively at screening for any of the following conditions a.
  • the subject has an active hepatitis B infection (acute or chronic) at screening as determined by hepatitis B serology (https://www.cdc.gov/hepatitis/hbv/pdfs/SerologicChartv8.pdf).
  • b. The subject has serology positive for hepatitis C virus antibody (HCV Ab).
  • c. The subject has human immunodeficiency virus (HIV) positive serology.
  • the subject has total IgG ⁇ 6 g/L at screening.
  • the subject has presence or sequelae of gastrointestinal, liver, kidney, or any other condition known to potentially interfere with the absorption, distribution, metabolism, or excretion of efgartigimod.
  • the subject has a history of malignancy unless deemed cured by adequate treatment with no evidence of recurrence for >3 years before first efgartigimod administration.
  • Subjects with the following cancer can be included anytime: a. Adequately treated basal cell or squamous cell skin cancer b. Carcinoma in situ of the cervix c. Carcinoma in situ of the breast or d. Incidental histological finding of prostate cancer (TNM stage Tla or Tib)
  • the subject has a clinically relevant abnormality detected on ECG recording regarding either rhythm or conduction (e.g., QTcF >450 ms for male and QTcF >470 ms for female subjects, or a known long QT syndrome).
  • a first-degree heart block or sinus arrhythmia will not be considered a significant abnormality.
  • the subject has clinically relevant abnormalities detected in vital sign measurements prior to dosing.
  • the subject has significant blood loss (including blood donation >500 mL) or has had a transfusion of any blood product within 12 weeks prior to the (first) efgartigimod administration or a scheduled transfusion within 4 weeks after the end of the study.
  • the subject has been treated with any drug known to have a well-defined potential for toxicity to a major organ in the last 3 months preceding the initial efgartigimod administration.
  • Regular consumption of a large quantity of coffee, tea (>6 cups per day), or equivalent within 3 weeks prior to first dose is also exclusionary.
  • the subject has received investigational drug within 3 months or 5 half-lives of the drug (whichever is longer) prior to first efgartigimod administration.
  • the subject has received a vaccination (e.g., influenza vaccine) within the last 4 weeks prior to screening.
  • the subject has received any systemic immunosuppressant agent within 6 months prior to the initial efgartigimod administration.
  • the subject has received any systemic steroid within 3 months prior to the initial efgartigimod administration.
  • the subject has received any monoclonal antibody, within 6 months prior to first efgartigimod administration.
  • the subject is an employee of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as a family member of an employee or the investigator.
  • the subject has any condition or circumstances that in the opinion of the investigator may make a subject unlikely or unable to complete the study or comply with study procedures and requirements.
  • the subject has any condition impairing phlebotomy. 37.
  • the subject is a pregnant or lactating women or intending to become pregnant during the study or within 90 days after last dosing.
  • the subject has a positive nasopharyngeal PCR test for SARS-CoV-2 on days -2 or -1.
  • the subject has had any contact with SARS-CoV-2 positive or CO VID-19 patients within the last 2 weeks prior to admission to the clinical research center.
  • the efgartigimod IV product is a 20R vial with an extractable volume of 20 mL.
  • One vial can deliver 400 mg efgartigimod.
  • the efgartigimod-PH20 SC product is a 10R vial with an extractable volume of 10 mL, at a concentration of 165 mg/mL.
  • the vial is ready to use and can deliver 1650 mg efgartigimod.
  • the primary objective of the study is to demonstrate that the PD effect of 4 once-weekly SC injections of 1000 mg efgartigimod-PH20 is non-inferior to that of 4 once- weekly intravenous infusions (IV) of efgartigimod at a dose of 10 mg/kg by comparing the percentage reduction in total immunoglobulin G (IgG) levels after 4 weeks (day 29), i.e., 1 week after the fourth administration, using a non-inferiority margin of 10%.
  • IgG immunoglobulin G
  • the primary endpoint of the study is the percentage reduction in total IgG levels, compared to baseline, at day 29 (week 4), 7 days after the fourth IV or SC administration of efgartigimod.
  • IgG subtypes IgGl, IgG2, IgG3, and IgG4
  • Efgartigimod concentration in serum was determined using a validated enzyme- linked immunosorbent assay (ELISA).
  • LLOQ lower limit of quantification
  • Concentrations were calculated by interpolation from a calibration curve. Quality control samples were analyzed throughout the study. Their measured concentrations were used to determine between-run, overall precision, and accuracy of the analyses.
  • the primary endpoint was defined as the percentage reduction in total IgG levels, compared to baseline, at day 29 (week 4), i.e., 7 days after the fourth IV or SC administration of efgartigimod.
  • Piv and p sc are the estimated averages in % reduction of total IgG after 4 weeks (day 29) in the group of subjects receiving efgartigimod as IV or SC administration, respectively.
  • ANCOVA covariance model
  • the primary endpoint for this study was defined as the percentage reduction in total IgG from baseline, 1 week after the fourth administration of study medication (i.e., day 29).
  • CI confidence interval
  • ANCOVA analysis of covariance
  • Table 10 Summary statistics for the comparison of percent change from baseline in total IgG between the efgartigimod IV and efgartigimod-PH20 SC treatment arms (IV- PH20 SC) for the first 4 weeks of treatment
  • PK profile after the fourth weekly administration of 1000 mg efgartigimod- PH20 SC or 10 mg/kg efgartigimod IV is presented in FIG. 19 and PK parameters are summarized in Table 12. For this interim evaluation, the PK parameters were estimated based on scheduled sampling times.
  • Cmax and AUCo iesh were approximately 80% and 15% lower, respectively, while Ctrough was approximately 50% higher after 1000 mg efgartigimod- PH20 SC compared with 10 mg/kg efgartigimod IV.
  • the apparent elimination half-life (ti/2) was comparable with mean (SD) values of 83.2 (16.3) hours and 75.6 (13.2) hours after 1000 mg efgartigimod-PH20 SC and 10 mg/kg efgartigimod IV, respectively.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PCT/IB2022/000443 2021-08-02 2022-08-02 Subcutaneous unit dosage forms Ceased WO2023012515A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2024506201A JP2024530152A (ja) 2021-08-02 2022-08-02 皮下単位剤形
KR1020247006620A KR20240040104A (ko) 2021-08-02 2022-08-02 피하 단위 투여 형태
CN202280059734.XA CN117897172A (zh) 2021-08-02 2022-08-02 皮下单位剂型
AU2022322077A AU2022322077A1 (en) 2021-08-02 2022-08-02 Subcutaneous unit dosage forms
IL310608A IL310608A (en) 2021-08-02 2022-08-02 Dosage forms for subcutaneous administration
EP22764840.9A EP4380618A2 (en) 2021-08-02 2022-08-02 Subcutaneous unit dosage forms
MX2024001631A MX2024001631A (es) 2021-08-02 2022-08-02 Formas de dosificación unitaria subcutánea.
CA3228105A CA3228105A1 (en) 2021-08-02 2022-08-02 Subcutaneous unit dosage forms
US18/431,585 US20240325528A1 (en) 2021-08-02 2024-02-02 Subcutaneous unit dosage forms

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163203856P 2021-08-02 2021-08-02
US63/203,856 2021-08-02

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US18/431,585 Continuation US20240325528A1 (en) 2021-08-02 2024-02-02 Subcutaneous unit dosage forms

Publications (2)

Publication Number Publication Date
WO2023012515A2 true WO2023012515A2 (en) 2023-02-09
WO2023012515A3 WO2023012515A3 (en) 2023-04-06

Family

ID=83192179

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2022/000443 Ceased WO2023012515A2 (en) 2021-08-02 2022-08-02 Subcutaneous unit dosage forms

Country Status (11)

Country Link
US (1) US20240325528A1 (https=)
EP (1) EP4380618A2 (https=)
JP (1) JP2024530152A (https=)
KR (1) KR20240040104A (https=)
CN (1) CN117897172A (https=)
AU (1) AU2022322077A1 (https=)
CA (1) CA3228105A1 (https=)
IL (1) IL310608A (https=)
MX (1) MX2024001631A (https=)
TW (1) TW202320849A (https=)
WO (1) WO2023012515A2 (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023209036A1 (en) * 2022-04-26 2023-11-02 argenx BV Methods for treating bullous pemphigoid using fcrn antagonists
US12202900B2 (en) 2018-06-08 2025-01-21 argenx BV Compositions and methods for treating immune thrombocytopenia
US12240875B2 (en) 2017-12-08 2025-03-04 argenx BV Use of FCRN antagonists for treatment of generalized myasthenia gravis
US12344678B2 (en) 2022-06-15 2025-07-01 argenx BV FcRn/HSA binding molecules and methods of use
US12403175B2 (en) 2020-01-08 2025-09-02 argenx BV Methods for treating pemphigus disorders
WO2025233684A1 (en) * 2024-05-10 2025-11-13 argenx BV Subcutaneous formulations, pre-filled syringes and methods of use thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767429B2 (en) 2003-03-05 2010-08-03 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US7829081B2 (en) 2005-02-23 2010-11-09 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US8187855B2 (en) 2008-03-06 2012-05-29 Halozyme, Inc. Large-scale production of soluble hyaluronidase
US8927249B2 (en) 2008-12-09 2015-01-06 Halozyme, Inc. Extended soluble PH20 polypeptides and uses thereof
US9447401B2 (en) 2011-12-30 2016-09-20 Halozyme, Inc. PH20 polypeptide variants, formulations and uses thereof
WO2020022791A1 (ko) 2018-07-25 2020-01-30 (주)알테오젠 신규 히알루론산 가수분해 효소 변이체 및 이를 포함하는 약제학적 조성물
WO2020197230A1 (ko) 2019-03-25 2020-10-01 (주)알테오젠 인간 히알루로니다제 ph20의 변이체와 약물을 포함하는 피하투여용 약학 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE028832T2 (en) * 2009-09-17 2017-01-30 Baxalta Inc Stable co-formulation of hyaluronidase and immunoglobulin, as well as a process for its preparation
CA3081144A1 (en) * 2017-12-08 2019-06-13 Argenx Bvba Use of fcrn antagonists for treatment of generalized myasthenia gravis
JP2023509195A (ja) * 2020-01-08 2023-03-07 アルジェニクス ビーブイ 天疱瘡症を治療する方法

Patent Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8202517B2 (en) 2003-03-05 2012-06-19 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US8450470B2 (en) 2003-03-05 2013-05-28 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US9677062B2 (en) 2003-03-05 2017-06-13 Halozyme, Inc. Hyaluronidase and factor VIII compositions
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US8105586B2 (en) 2003-03-05 2012-01-31 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US7767429B2 (en) 2003-03-05 2010-08-03 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US8772246B2 (en) 2003-03-05 2014-07-08 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US8431124B2 (en) 2003-03-05 2013-04-30 Halozyme, Inc. Methods for treating a disease characterized by an excess of hyaluronan by administering a soluble hyaluronidase glycoprotein (sHASEGP)
US9677061B2 (en) 2003-03-05 2017-06-13 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US8431380B2 (en) 2003-03-05 2013-04-30 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US8765685B2 (en) 2003-03-05 2014-07-01 Halozyme, Inc. Methods for treating edema by administering a Soluble Hyaluronidase Glycoprotein (sHASEGP)
US8580252B2 (en) 2004-03-05 2013-11-12 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US8257699B2 (en) 2004-03-05 2012-09-04 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US7829081B2 (en) 2005-02-23 2010-11-09 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US7846431B2 (en) 2005-02-23 2010-12-07 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US8187855B2 (en) 2008-03-06 2012-05-29 Halozyme, Inc. Large-scale production of soluble hyaluronidase
US8927249B2 (en) 2008-12-09 2015-01-06 Halozyme, Inc. Extended soluble PH20 polypeptides and uses thereof
US9447401B2 (en) 2011-12-30 2016-09-20 Halozyme, Inc. PH20 polypeptide variants, formulations and uses thereof
US10865400B2 (en) 2011-12-30 2020-12-15 Halozyme, Inc. PH20 polypeptide variants, formulations and uses thereof
WO2020022791A1 (ko) 2018-07-25 2020-01-30 (주)알테오젠 신규 히알루론산 가수분해 효소 변이체 및 이를 포함하는 약제학적 조성물
WO2020197230A1 (ko) 2019-03-25 2020-10-01 (주)알테오젠 인간 히알루로니다제 ph20의 변이체와 약물을 포함하는 피하투여용 약학 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CAS, no. 1821402-21-4

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12240875B2 (en) 2017-12-08 2025-03-04 argenx BV Use of FCRN antagonists for treatment of generalized myasthenia gravis
US12202900B2 (en) 2018-06-08 2025-01-21 argenx BV Compositions and methods for treating immune thrombocytopenia
US12403175B2 (en) 2020-01-08 2025-09-02 argenx BV Methods for treating pemphigus disorders
WO2023209036A1 (en) * 2022-04-26 2023-11-02 argenx BV Methods for treating bullous pemphigoid using fcrn antagonists
US12344678B2 (en) 2022-06-15 2025-07-01 argenx BV FcRn/HSA binding molecules and methods of use
US12565538B2 (en) 2022-06-15 2026-03-03 argenx BV FCRN/antigen-binding molecules and methods of use
WO2025233684A1 (en) * 2024-05-10 2025-11-13 argenx BV Subcutaneous formulations, pre-filled syringes and methods of use thereof

Also Published As

Publication number Publication date
IL310608A (en) 2024-04-01
WO2023012515A3 (en) 2023-04-06
CN117897172A (zh) 2024-04-16
KR20240040104A (ko) 2024-03-27
US20240325528A1 (en) 2024-10-03
TW202320849A (zh) 2023-06-01
JP2024530152A (ja) 2024-08-16
AU2022322077A1 (en) 2024-02-08
CA3228105A1 (en) 2023-02-09
MX2024001631A (es) 2024-04-19
EP4380618A2 (en) 2024-06-12

Similar Documents

Publication Publication Date Title
US20240325528A1 (en) Subcutaneous unit dosage forms
AU2017265049B2 (en) Anti-VLA1 (CD49A) Antibody Pharmaceutical Compositions
US20250195649A1 (en) High Concentration Bispecific Antibody Formulations
TR201808801T4 (tr) İmmünoglobulin formülasyonu ve bunun hazırlanış yöntemi.
TW201709927A (zh) 使用ＡＣＴＲＩＩ配位體捕捉以治療β－地中海型貧血
EP3043774A2 (en) Liquid protein formulations containing ionic liquids
EP4243928B1 (en) Anti-gdf15 antibody and a dosage regimen for the treatment of cancer
EP3868785A1 (en) Anti-cd28 humanized antibodies formulated for administration to humans
KR20250109193A (ko) Fcrn 길항제를 사용하여 루푸스 신염을 치료하는 방법
CN118105512A (zh) 含有hGH融合蛋白的治疗生长激素缺乏症的药物组合物
WO2021147854A1 (zh) 重组全人源抗tigit单克隆抗体制剂及其制备方法和用途
US20250352617A1 (en) Taci-fc fusion protein liquid pharmaceutical preparation
US20240034813A1 (en) High Concentration Bispecific Antibody Formulations
HK40104320A (zh) 皮下单位剂型
WO2025029873A9 (en) Treatment of hair-loss disorder
WO2025224506A1 (en) Methods for reducing platelet degradation using fcrn antagonists
WO2025179012A1 (en) Compositions and uses of tumor activated antibodies targeting egfr and effector cell antigens
HK40119812A (en) Taci-fc fusion protein liquid pharmaceutical preparation
NZ717918B2 (en) Liquid protein formulations containing ionic liquids

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22764840

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2022322077

Country of ref document: AU

Ref document number: 807613

Country of ref document: NZ

Ref document number: AU2022322077

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 12024550251

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 2024506201

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 3228105

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 202417006714

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 310608

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2022322077

Country of ref document: AU

Date of ref document: 20220802

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112024002013

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 202490316

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 20247006620

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 11202400439V

Country of ref document: SG

WWE Wipo information: entry into national phase

Ref document number: 202280059734.X

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022764840

Country of ref document: EP

Effective date: 20240304

ENP Entry into the national phase

Ref document number: 112024002013

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20240131